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Abstract 
Background: Diabetes Mellitus (DM) is associated with both micro- and macro- 
vascular complications, linked to hyperglycemia and atherosclerotic chronic 
inflammation of the vessels. The endothelium is the prime organ to be exposed to 
hyperglycemia and is one of the main targets of diabetic complications. 
Proteoglycans (PGs) are important components of the healthy endothelium, and are 
also involved in a number of processes important to the development of DM and 
atherosclerosis. Thus, changes in PG expression might be linked to the development 
of diabetic complications.  
Methods: Primary human umbilical vein endothelial cells (HUVEC) were 
established and cultured in vitro. In order to study the changes in PGs during DM, we 
mimicked the diabetic conditions by exposing endothelial cells to a hyperglycaemic 
or inflammatory environment. Hyperglycemic exposure was either high glucose (25.0 
mM) or glucosamine (GlcN; 0, 0.1, 1.0, 2.0, 5.0 or 10.0 mM), and inflammatory 
conditions were created by adding pro-inflammatory cytokines interleukine-1α (IL-
1α, 2 ng / ml) or tissue necrosis factor-α (TNF-α, 7 ng / ml). Low glucose (5.0 mM) 
was used as the control in all experiments. 35S-sulfate labelling was performed 24 
hours prior to harvesting. Radiolabelled macromolecules were obtained by 
gelfiltration chromatography; in some cases PGs were further isolated by ion-
exchange chromatography, before separation on SDS-PAGE and visualization by 
film exposure. Cells cultured for Western blotting analyses were stimulated for 24 
hours before harvesting, isolation of PGs by ion-exchange chromatography, SDS-
PAGE separation, electroblotting and immunostaining against PGs perlecan and 
decorin.  
Results: GlcN dose-response and time-response experiments indicated a suitable 
exposure of 1.0 mM GlcN for 24 hours in HUVEC. The major findings revealed a 
decreased biosynthesis and secretion of 35S-PGs and of the individual PGs perlecan 
and decorin upon GlcN exposure. The effects of high levels of glucose were 
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inconclusive. Exposure of HUVEC to the pro-inflammatory cytokine IL-1α increased 
the total de novo synthesis of PGs, while the effects of TNF-α were inconclusive. 
Only decorin was increased by the cytokines, not perlecan. Both during 
hyperglycaemic and inflammatory conditions however, no effects on the heparan 
sulfate (HS) / choindroitin sulfate (CS) ratio of the total PG pool were observed, nor 
on the HS/CS composition of the individual PGs perlecan and decorin. Perlecan was 
demonstrated to be a HSPG in HUVEC. 
Conclusions: The experiments indicated a suitable exposure of 1.0 mM GlcN for 24 
hours in HUVEC, affecting PG expression without affecting cell viability. The 
decrease in PGs after GlcN exposure suggests an effect of hyperglycemia on PG 
expression trough the hexosamine pathway. GlcN is most likely to influence on the 
total expression of PGs. These effects were, however, not observed in cells exposed 
to high glucose. IL-1α, but not TNF-α, was indicated to increase PG expression. The 
HS/CS composition was not observed to be altered with high glucose or GlcN 
treatment. Decorin expression was altered upon cytokine exposure, but not perlecan. 
This might suggest a different effect on various PGs by inflammatory mediators. 
Additional analyses are clearly demanded to clarify the causes of the observed 
changes in PG expression; it must be elucidated whether these changes reflects 
changes in PG synthesis, degradation, or rather in glycosaminoglycan composition, 
length and sulfation.   
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1. Abbrevations 
AGE Advanced Glycation End products 
BM Basement Membrane 
cABC chondroitinase ABC 
Cpm Counts per minute 
CS Choindroitin sulfate 
DAG Diacylglycerol 
DEAE  Diethylaminoethyl 
DHAP Dihydroxyacetone phosphate 
DM Diabetes Mellitus 
DMSO Dimethyl sulfoxide 
DS Dermatan sulfate 
EC Endothelial cell 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor 
EGFR  Epidermal growth factor receptor 
eNOS endothelial nitric oxide synthase 
FCS Foetal Calf Serum 
FGF Fibroblast Growth Factor 
GAG Glycosaminoglycan 
Gal Galactose 
GalN Galactosamine 
GalNAc N-Acetyl Galactosamine 
GAPDH Glyceraldehyde-3 phosphate dehydrogenase 
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GFAT Glutamine:fructose-6 phosphate amidotransferase 
GlcA Glucuronic acid 
GlcN Glucosamine 
GlcNAc N-Acetyl Glucosamine 
Gln Glutamine 
Glu Glutamic Acid 
GLUT Glucose transporter 
HA Hyaluronic acid / hyaluronan 
HbA1c Glycated Haemoglobin A1c 
HG High glucose 
HS Heparan sulfate 
HUVEC Human Umbilical Vein Endothelial Cell 
IdoA Iduronic acid 
KS Keratan sulfate 
LG Low glucose 
NADH/NAD+ Nicotinamide adenine dinucleotide  
NADPH/NADP+ Nicotinamide adenine dinucleotide phosphate 
PAI-1 Plasminogen Activator Inhibitor - 1 
PARP Poly ADP-ribose polymerase 
PBS Phosphate Buffered Saline 
PDGF Platelet Derived Growth Factor 
PG Proteoglycan 
PKC Protein Kinase C 
RAGE Receptor for AGE  
ROS Reactive Oxygen Species 
SLRP Small Leucine Rich PGs 
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SMC Smooth Muscle Cells 
TGF-β Transforming Growth Factor -β 
UDP Uridine diphosphate 
VEGF Vascular Endothelial Growth Factor 
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2. Introduction 
The altered way of living of humans towards a more sedentary lifestyle with a higher 
consumption of sugar and fat, has lead to an increase in life-style related diseases 
such as metabolic syndrome and type II diabetes (1). Diabetes Mellitus (DM) reduce 
the life quality and life-expectancy of the patient, as well as being costly for the 
society. DM is associated both with hyperglycemia and atherosclerotic chronic 
inflammation of the vessels. The endothelium lining the vessels is the prime organ to 
be exposed to hyperglycemia and is one of the main targets of diabetic complications. 
The structurally diverse and widespread proteoglycans (PGs) are involved in a 
number of different processes important in the development of DM and 
atherosclerosis. Changes in PG expression could thus be involved in the development 
of diabetic complications. In order to study changes in endothelial PG expression 
during diabetic conditions, we mimic these conditions by exposing cultured human 
endothelial cells to hyperglycaemic conditions or inflammatory cytokines, and study 
the effects on proliferation, total PG production and changes in the expression of 
individual PGs.  
2.1 Diabetes Mellitus 
DM is responsible for 5 % of all deaths globally each year, and this number is likely 
to increase by more than 50 % over the next 10 years. In Norway there are probably 
between 90 000 and 120 000 people with diagnosed DM, and nearly as many may 
with undiagnosed DM (2). An estimated number of 171 million people are diagnosed 
with DM worldwide. The total number of diabetics will be more than doubled over 
the next 25 years, reaching a total of 366 million globally by 2030 (3). This increase 
is mostly due to an addition in the prevalence of type II DM, and occurs because of 
the growing trend towards obesity, unhealthy diets with a higher consumption of 
sugar and fat and more sedentary lifestyles (1).  
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DM is a group of metabolic diseases steadily increasing in prevalence all over the 
world. DM is characterized by chronic hyperglycemia caused by lacking production 
of – or response to –insulin. The anabolic hormone insulin decreases the amount of 
glucose in the blood by promoting glucose uptake by cells and increasing the 
capacity of the liver to synthesize glycogen. There are three main forms of DM: type 
I, type II and gestational DM, which have similar signs, symptoms and consequences, 
but different causes and population distribution. Type I DM is characterized by the 
autoimmune destruction of the insulin-producing β-cells of the pancreas, leading to 
failure to produce insulin and hence impaired uptake of glucose. In type II DM the 
hyperglycemia is caused by insulin-resistance or reduced insulin sensitivity in 
combination with reduced insulin secretion. The pancreas increases the production of 
insulin in response to lowered sensitivity in liver, muscle and fat. This extra workload 
exhausts the β-cells and the insulin production declines over time, resulting in a 
relative insulin-deficiency (4). Finally, gestational DM is defined as "any degree of 
glucose intolerance with onset or first recognition during pregnancy" (5). The 
hormones of pregnancy can cause insulin resistance in predisposed women. This 
condition typically resolves after delivery, but can have severe consequences for the 
foetus. The causes of type I DM is not clear, but it could possibly be triggered by for 
example viral infections in genetic susceptible individuals, and it often attacks young 
people. The much more common type II DM is on the other hand provoked by 
lifestyle factors and its prevalence increases with increasing age, although this age is 
now declining.  
2.2 The endothelium 
The endothelium is the thin layer of cells that line the interior surface of blood 
vessels, forming an interface between circulating blood in the lumen and the rest of 
the vessel wall. Endothelial cells (ECs) are specialized epithelium cells which line the 
entire circulatory system, from the heart to the smallest capillary. They synthesize 
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molecules released to the blood and to the extracellular matrix (ECM), and control 
the passage of materials into and out of the bloodstream. The endothelium senses 
mechanical and hormonal stimuli, and responds to this by releasing agents that 
regulate vasomotor function (NO, endothelin-1, angiotensin II), trigger inflammatory 
processes (NO, adhesion molecules) and affect homeostasis (6). Dynamic interactions 
between ECs and components of their surrounding ECM are necessary for the 
invasion, migration and survival of EC during angiogenesis. These interactions are 
mediated by EC receptors recognizing ECM components; integrins and cell surface 
PGs, and are also modulated by matrix proteinases that proteolytically degrade matrix 
components (7). Thus, the endothelium is either directly or indirectly involved in 
many human diseases such as atherosclerosis, coagulation disorders, malignant 
growth, and chronic diseases including DM and arthritis.  
 
Figure 2.1. Illustration of different vessels and the endothelium.  A. A small artery in cross 
section showing the inner lining of endothelial cells and the surrounding layer of smooth 
muscle cells and connective tissue. B. Electron micrograph of a small capillary cross-
section. The wall is formed by a single endothelial cell surrounded by basement membrane. 
From Alberts, B. et al, Molecular biology of the Cell, 3ed (8). 
The largest blood vessels (arteries and veins) have a thick tough wall of connective 
tissue and smooth muscle cells (SMC), and this wall is lined by a thin single layer of 
ECs, separated from the surrounding outer layers by a basement membrane (BM) 
(figure 2.1A). The amount of connective tissue and SMC in the vessel wall varies 
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according to the vessel’s diameter and function, but the endothelial lining is always 
present. In the capillaries the walls consists of nothing but ECs and basal lamina as 
shown in figure 2.1B (8). Covering the endothelium luminally is the endothelial 
glycocalyx; a network of membrane-bound PGs and glycoproteins (9). Both plasma 
and endothelial derived soluble molecules are incorporated into this network, and a 
dynamic equilibrium exists between this layer of soluble components and the flowing 
blood. Figure 2.2 provide a schematic illustration of the construction of the 
endothelium. 
 
 
Figure 2.2. Structure of the vessel wall. The blood vessels have a wall of connective tissue 
and smooth muscle cells (tunica media and adventitia), and this wall is lined by a thin single 
layer of ECs, separated from the surrounding outer layers by a basal membrane (tunica 
intima). PGs are important constituents of both the ECM and the basement membrane. 
Covering the endothelium luminal is the endothelial glycocalyx; a network of membrane-
bound PGs and glycoproteins. Modified from: 
http://en.wikipedia.org/wiki/Image:Anatomy_artery.png  
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2.3 DM complications 
The chronic hyperglycemia of DM is important in the pathogenesis of specific DM-
related micro- and macro- vascular complications (10). Diabetic microangiopathy can 
cause retinopathy, neuropathy and nephropathy (11). Macroangiopathy – mainly 
atherosclerosis of the coronary, carotid and peripheral arteries - increase the risk of 
myocardial infarction, stroke and diabetic foot disease. DM is thus an important cause 
of blindness, limb amputation and kidney failure, and 50% of diabetic die of 
cardiovascular disease. Hyperglycemia plays an important role in the development of 
microvascular complications, along with hypertension, smoking, 
hypercholesterolemia, dyslipidemia, obesity and hyperhomocysteinaemia (6). The 
risk of macroangiopathy is not so strongly related to hyperglycemia, but more so to 
the general risk factors of atherothrombosis, all of which create a constant damage to 
the vascular wall manifested by a low-grade inflammatory process and endothelial 
dysfunction. 
The treatment of DM was very limited until insulin became medically available in 
1921. Today the disease is usually managed with a combination of insulin 
supplementation, tablets (type II), dietary treatment, exercise, and weight loss. Two 
landmark studies, the DCCT (The Diabetes Control and Complications Trial) (12) 
and UKPDS (United Kingdom Prospective Diabetes Study) (13), showed that 
intensive control of hyperglycemia can reduce the occurrence of progressive retino- 
neuro- and nephropathy in diabetic patients. Important goals in preventing long-term 
diabetic complications are keeping fasting blood glucose concentration between 4 
and 7 mM, and avoiding a postprandial concentration above 10 mM. The level of 
HbA1c (glycated hemoglobin A1c) reflects the average plasma glucose concentration 
over longer periods of time, and should be held below 7.5 % in diabetics (14).  
2.3.1 Endothelial dysfunction 
The endothelium is the prime organ to be exposed to the hyperglycemia of DM, and 
hyperglycemia is identified as a primary causal factor in the development of DM 
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complications, and might be responsible for impairment of significant functions of 
the endothelium (12;13). The endothelium is especially vulnerable to hyperglycemia 
because of the inability to regulate the glucose uptake, resulting in high intracellular 
levels during hyperglycemic conditions. ECs and SMCs express GLUT 1 (Glucose 
transporter 1) which is not responsive to insulin, but they do not express GLUT 2-5, 
and thus cannot regulate glucose uptake trough insulin action (15;16). Also, SMCs 
are able to downregulate GLUT 1, while ECs are not (16). This is reflected in the fact 
that diabetic complications appear to affect organs where cells do not require insulin 
for uptake, such as EC, mesangial cells in the renal glomerulus and neurons and 
Schwann cells in peripheral nerves.  
Endothelial dysfunction is a key component in the pathogenesis of atherosclerosis. It 
is a broad term that implies an impairment of the normal functions of the 
endothelium. This is characterized by a shift toward reduced vasodilation caused by 
impaired NO generation, a proinflammatory state and increase in prothrombotic 
properties (17). Besides the vasodilatory effects, NO inhibits leukocyte adhesion to 
the endothelial cells, and reduce platelet aggregability and SMC proliferation, and 
thus protects against inflammation (18). Up-regulation of adhesion molecules, 
generation of chemokines and production of PAI-1 (plasminogen activator inhibitor-
1) participate in the inflammatory response and contribute to the prothrombotic state.  
Important changes associated with microvascular complications are the thickening of 
the basement membrane, reduction of glycocalyx dimensions (19;20), increased 
organ blood flow and vascular permeability, and abnormal blood viscosity, platelet 
function – all of which originates, at least in part, in the endothelial dysfunction. 
Macrocvascular complications include disease of the larger vessels, or essentially, 
atherosclerosis. 
The thickening of the capillary BM observed in DM (21) is to a large part due to an 
increase in type IV collagen secretion by the capillary cells, reduced PG expression 
and alterations in ECM network formation. BM thickening could cause vascular 
dysfunction by several different mechanisms: Alterations in BM compounds could 
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affect vascular cell metabolism and impair functions such as migration, cell adhesion 
and growth.  A decrease in negative charges due to altered PG composition could 
change the filtration properties of renal glomerular capillaries, and glycated 
extracellular proteins can bind to specific receptors and affect vascular cell 
metabolism and function directly. Degraded products of BM can alter vascular cell 
growth indirectly by initially activating macrophages, which then release vasoactive 
cytokines (21). Acute and long standing hyperglycemia is also associated with 
profound reduction of glycocalyx dimensions, and it is speculated that this damage to 
the glycocalyx contribute to the endothelial dysfunction in hyperglycemic conditions. 
The role of endothelial glycocalyx in atherogenesis is not well-established but data 
suggests that it is involved in the initiation and progress of the atherosclerotic process 
(19).  
2.3.2 Mechanisms underlying endothelial dysfunction in DM 
DM is associated with micro- and macro vascular complications; affecting the small 
vessels such as those supplying the retina, nerves and kidneys, and the large arteries 
of the limbs and coronary arteries, respectively. Hyperglycemia is established as a 
major risk factor contributing to the underlying endothelial dysfunction and low 
grade inflammation of this angiopathy (12;13). This relationship is illustrated in 
figure 2.4. There are four main hypotheses linking hyperglycemia to diabetic 
complications: increased hexosamine pathway flux, increased AGE (Advanced 
Glycation End products) formation, activation of PKC (protein kinase C) and 
increased polyol pathway flux (11;22), see figure 2.3 (22).  
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Figure 2.3. Overview of the metabolic pathways of glucose, linking hyperglycemia to 
diabetic complications. Excess superoxide partially inhibits the glycolytic enzyme GAPDH 
(glyceraldehyde-3 phosphate dehydrogenase), thereby diverting upstream metabolites from 
glycolysis into pathways of glucose overutilization. This results in increased flux of DHAP 
(dihydroxyacetone phosphate) to DAG (Diacylglycerol), an activator of PKC, and of triose 
phosphates to methylglyoxal, the main intracellular AGE precursor. Increased flux of 
fructose-6-phosphate to UDP-N-acetylglucosamine increases modification of proteins by O-
linked N-acetylglucosamine (GlcNAc) and increased glucose flux through the polyol 
pathway consumes NADPH and depletes glutathione. From Brownlee, M. Nature, 2001(22). 
Figure 2.4. Illustration of the 
relationship between hyper -
glycemia, endothelial dys- 
function and diabetic 
complications. Diabetes is 
associated with micro- and macro 
vascular complications; affecting 
the small vessels such as those 
supplying the retina, nerves and 
kidneys, and the large arteries of 
the limbs and coronary arteries, 
respectively. Hyperglycemia is 
established as a major risk factor 
contributing to the underlying 
endothelial dysfunction and low 
grade inflammation of this 
angiopathy. 
The Hexosamine pathway 
The increase of intracellular glucose and glucose metabolites will increase the flux 
trough several metabolic pathways. Shunting of excess intracellular glucose into the 
hexosamine pathway is one of the ways in which hyperglycemia might contribute to 
the diabetic complications. Exposure to excess glucosamine (GlcN) is thought to 
exert the same effects trough entering this pathway as indicated in figure 2.5. GlcN 
taken up by cells is phosphorylated into GlcN 6-phosphate by hexokinase, which then 
bypasses GFAT (glutamine:fructose-6 phosphate amidotransferase) to enter the 
hexosamine pathway.  
 
Figure 2.5. The hexosamine pathway. Glucose (Gluc) is taken up by cells and metabolized 
trough the glycolysis or other metabolic pathways such as the hexosamine pathway. In the 
latter, glucose is converted to GlcN-6-phosfate (GlcN-6-P) by the enzyme GFAT 
(glutamine:fructose-6 phosphate amidotransferase). GlcN-6-P is further converted to N-
Acetyl-Glucosamine-6-fosfate (GlcNAc-6-P) andGlcNAC-1-P, and then to the Uridine 
diphosphate-sugars UDP-GlcNAc and UDP GalNAc (N-Acetyl-galactosamine). The rate-
limiting step of GFAT can be avoided by direct administration of GlcN, which is converted 
to GlcN-6-P by a hexokinase.  UDP-GlcNAC and UDP-GalNAc are utilized for GAG 
(glucosaminoglycan) -synthesis and protein glycosylation. An increase in UDP-sugars is 
believed to increase the GAG-synthesis, and thus alter the PG expression. An increase in 
glucose availability will create excess superoxide, partially inhibiting the glycolytic enzyme 
GAPDH, and thereby diverting upstream metabolites from glycolysis into pathways of 
glucose overutilization. This results in increased flux of the hexosamine pathway, and 
possibly a change in PG expression. 
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Some of the fructose-6-phospate from the glycolysis is converted by the enzyme 
GFAT into glucosamine-6-phosphate (GlcN-6P) and finally to UDP-GlcNAc, which 
is required for N-linked and O-linked glycosylation and the GAG 
(glucosaminoglycan) synthesis of PGs (23). The substrate affinity of GFAT is 
relatively low, and during normoglycemic conditions, the flux trough this pathway is 
scarce; about 1-2% of the incoming glucose enters this pathway (24). During 
hyperglycemia however, the flux is markedly increased (25). This increased 
production of GlcNAc could lead to altered modification of transcription factors, 
often resulting in pathological changes in gene expression. As an example, increased 
modification (O-GlcNAcylation) of the transcription factor Sp1 will result in 
increased expression of TGF-β (Transforming growth factor-β) and PAI-1, both of 
which have negative effects for diabetic blood vessels (26). Activation of the 
hexosamine pathway may result in many changes both in gene expression and protein 
function, which together could contribute to the pathogenesis of diabetic 
complications. It could also affect the synthesis of PGs directly by increasing the 
availability of UDP sugars, substrates of GAG synthesis. 
AGE formation 
Advanced Glycation End products (AGEs) are the results of a chain of chemical 
reactions after an initial glycation reaction, and the formation and accumulation of 
AGEs will increase in hyperglycaemic conditions. The formation of AGEs damage 
vascular cells in several ways; by modification of intracellular proteins, including 
proteins involved in the regulation of gene transcription, by modification of ECM 
components, interfering with matrix-matrix, matrix-cell and cell-cell interactions, and 
finally by modification of plasma proteins able to bind and activate RAGE 
(Receptors for AGE), inducing receptor mediated ROS (reactive oxygen species) 
production and activation of transcription factor NFκB. This will increase 
proinflammatory gene expression, including expression of cytokines and growth 
factors (TNF, IL, TGFβ) (11;18;27) as well as interleukins and adhesion molecules 
(28). The levels of AGE are increased in blood in persons suffering from DM (27). 
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The polyol pathway 
The first enzyme of the polyol pathway, aldose reductase, normally has the function 
of reducing toxic aldehydes in the cell to inactive alcohols. When glucose 
concentration becomes too high aldose reductase will also catalyze the NADPH 
dependent reduction of glucose into sorbitol, which is further reduced to fructose by 
sorbitol dehydrogenase. Hyperglycaemic conditions increase the flux through this 
pathway, consuming NADPH and at the same time decreasing the regeneration of the 
critical intracellular antioxidant glutathione from glutathione disulfide by NADPH. 
By reducing the amount of glutathione, the polyol pathway increases susceptibility to 
intracellular oxidative stress (11;22). 
The PKC pathway 
DAG and PKC are critical intracellular signalling molecules that can regulate many 
vascular functions, including permeability, vasodilator release, endothelial activation 
and growth factor signalling. Hyperglycemia increases DAG (diacylglycerol) content, 
which activates PKC. This has a number of pathogenic consequences by affecting the 
expression of eNOS (endothelial nitric oxide synthetase), endothelin-1, VEGF 
(vascular endothelial growth factor), TGF-β and PAI-1, and by activating NF-κB and 
NAD(P)H oxidases. Activation of PKC can thus produce vascular damage including 
increased permeability, NO dysregulation, increased leukocyte adhesion and 
alterations in blood flow (11;22).  
 
Each of these four pathogenic mechanisms reflects a single unifying process - the 
overproduction of superoxide by the mitochondrial electron transport chain generated 
during hyperglycemia. The glycolytic enzyme GAPDH (glyceraldehyde-3 phosphate 
dehydrogenase) catalyses the reduction of glyceraldehyde-3-phospate into 1,3-
diphosphoglycerate. Superoxide overproduction will inhibit GAPDH by activating 
PARP (poly ADP-ribose polymerase), accumulating upstream glucose-metabolites, 
increasing the flux trough the mentioned pathways (10;22).  
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Hyperglycemia is the major determinant of microvascular disease, however, not of 
macrovascular disease. In macrovascular endothelium however, insulin resistance 
increase free fatty acid flux into the cells, increasing free fatty acid oxidation by the 
mitochondria. This cause mitochondrial overproduction of ROS just like 
hyperglycemia does in microvasculature, activating the same damaging pathways.  
(11;27) Also, sustained high blood sugar will increase the production of AGE causing 
dysfunctional changes in the endothelium making it less elastic and more permeable. 
Additionally, increased AGE formation is linked to the oxidation of LDL-particles, 
making them more atherogenic. Together this will increase the risk of atherosclerosis, 
thrombosis and heart infarction, making the formation of AGE a contributor to the 
development of cardiovascular disease in diabetics. 
Inflammation 
Hyperglycemia contributes to the chronic inflammation seen in endothelial 
dysfunction. Although inflammation is a protective response, this response is also the 
basis of chronic diseases such as atherosclerosis (18). The inflammatory response is 
initiated by the adhesion of circulating monocytes to selectins and integrins on the 
endothelium (This relationship is also illustrated in figure 2.15, section 2.5). The 
expression of these adhesion molecules are upregulated during hyperglycemia and 
inflammation. Monocytes extravase into the target tissue, where they differentiate 
into macrophages. In the ateroma, macrophages express scavenger receptors to bind 
modified LDL, and these receptors are also increased in hyperglycemia. Activated 
macrophages secrete a variety of biologically active products amplifying the 
inflammatory response, including the cytokines and growth factors, continuing the 
vicious cycle. Thus, hyperglycemia is associated with increased production of pro-
inflammatory cytokines such as TNF-α, IL-1α and growth factors such as TGF-β 
(18). TNFα has been shown to be an independent risk marker both for cardiovascular 
disease and DM (29). 
Cytokines are soluble mediators of the immune system. The major inflammatory 
endocrine cytokines TNF and IL-1 are increased by a variety of inflammatory 
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mediators, including hyperglycemia. Both induce endothelial activation with 
increased expression of adhesion molecules, secretion of additional cytokines and 
growth factors, and NO production. Activation of the transcription factor NFκB is 
crucial in cytokine regulation of gene expression in ECs. NFκB is also activated by 
TNF-α, IL-1, hyperglycemia, AGEs, Angiotensin II, oxidized lipids and insulin, and 
regulate the inflammatory response and vascular cell function by regulating genes 
like cell-adhesion molecules, ILs, PAI-1 and NOS (6), and are thus important in the 
pathogenesis of vascular disease in DM. TGF-β is an anti-inflammatory and pro-
fibrotic growth factor, regulating cellular functions such as cell growth, death / 
apoptosis and differentiation. It is a potent inducer of ECM protein synthesis, also 
affecting PG synthesis. There is evidence that TGF-β play a major role in the 
development of diabetic nephropathy, in part by inducing the thickening of the BM. 
In contrast, TGF-β has potent anti-inflammatory effects on vascular cells, down-
regulating cytokine-induced expression of adhesion-molecules (6).  
2.4 Proteoglycans 
PGs are diverse and widespread molecules, also found in the endothelium, and are 
important both in endothelial function and dysfunction. The production and structure 
of PGs change during hyperglycemia and inflammation, and are thought to influence 
the progression of diabetic complications (30-33). In order to understand this 
relationship, it is necessary to study changes in PG expression and structure in 
relation to hyperglycemia and inflammation.  
2.4.1 Structure & Function 
PGs are glycoproteins covalently attached to one or more GAG chains. GAGs are 
long, linear polymers of a repeating disaccharide, of variable length and variable 
degree of modifications by sulfation, acetylation and epimerization. The 
disaccharides are composed of an uronic acid and a hexosamine (The uronic acids are 
either glucuronic acid, GlcA or iduronic acid, IdoA and the hexosamines are 
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glucosamine, GlcN or galactosamine, GalN). These give rise to the different GAGs 
heparan sulfate HS/heparin (GlcA/IdoA + GlcNAc), choindroitin sulfate CS (GlcA + 
GalNAc), dermatan sulfate DS (IdoA+GalNAc), keratin sulfate KS (Gal + GlcNAc) 
and hyaluronic acid (hyaluronan) (GlcA + GlcNAc), see figure 2.6. Hyaluronic acid 
is an unsulfated GAG which does not occur as a PG bound to a protein, but rather in 
free form or in complexes with other ECM components. Heparin is distinguished 
from HS by a higher degree of sulfation and higher proportion of IdoA. DS is in fact 
a CS 4 –sulfate GAG where a large percentage of GlcA is epimerized to IdoA. One 
unique feature of most GAGs is sulfation at different positions, increasing the 
negative charge and the ability to interact with partner molecules.   
 
Figure 2.6. Structure of the different GAGs and their hexosamine and uronic acid 
building blocks. The different GAGs are composed of repetitions of one of the above 
disaccharides. Each disaccharide is composed of a hexosamine (glucosamine GlcN or 
galactosamine GalN) and an uronic acid (glucuronic acid GlcA or Iduronic acid IdoA). 
These combinations give rise to the different GAGs heparan sulfate / heparin, Choindroitin 
sulfate), dermatan sulfate, keratin sulfate and hyaluronic acid (hyaluronan) which structures 
are indicated in this figure. The GAGs can be sulfated in the indicated positions. Taken 
from:  http://courses.cm.utexas.edu 
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The different PGs can be classified according to their GAGs, their topographical 
distribution, their functions or ultimately according to their core protein. They are 
referred to by trivial names that relate to structural or functional features of the 
respective macromolecules. The most common PGs are listed in table 2.1 along with 
some important features. 
Table 2.1. Overview of the most common PGs based on their localization (intracellular, 
cell surface and matrix) and some of their most common features (type and number of 
GAGs, size of core protein).  
PGs     PG 
GAG sort / 
no 
Protein core 
kDa 
Intracellular     serglycin HS/CS 8 17 
Cell surface GPI-coupled   glypican 1-5 HS/CS 3 57-69 
  Integral   syndecan-1 3HS+2CS 30,6 
      syndecan-2 2 HS 20,4 
      syndecan-3 3HS+ 2CS 44,6 
      syndecan-4 2 HS 19,5 
      D-syndecan 2 HS 39 
      β-glycan CS/DS 1 36 
Matrix Aggrecans   versican CS/DS 10-30 265-370 
  (hyalectans - PGs    aggrecan KS/CS >100 220 
  interacting with   brevican CS 1-3 100 
  Hyaluronan & lectins)   neurocan CS 3-7 136 
  SLRP's class I decorin CS/DS 1 40 
  (small leucine rich)    biglycan CS/DS? 2 35 
    class II fibromodulin KS 2-3 41 
      lumican KS 3-4 38 
      keratocan KS 3-5 38 
      PRELP KS 2-3 44 
      osteodherin KS 2-3 42 
    classIII epiphycan DS/CS 2-3 35 
      osteoglycin KS 2-3 35 
  Basement -   perlecan HS/CS 3 400-467 
  membrane   agrin HS 3 250 
      bamacan CS 3 138 
 
As table 2.1 illustrate, the PGs are very diverse. The size of the core protein ranges 
from 10 to > 500 kDa, and the number of GAG chains attached varies from 1 to >100 
(23). Figure 2.7 illustrate the difference in size and structure in different PGs. The 
GAG chains vary in type and length, are modified in different ways, and in addition, 
several PGs carry GAGs of more than one type or have additional N-linked or O-
linked sugar modifications. Also, ‘part-time’ PGs exists, proteins in which only a 
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portion has GAG chains attached. PGs are found intracellular (usually in secretory 
granules), at the cell surface, and as part of the ECM, including the BM and the 
glycocalyx. Their biological roles are as diverse as their structures, ranging from 
simple mechanical support in the ECM, to more intricate effects on processes such as 
cell adhesion, motility and proliferation. Most of the effects depend upon binding of 
proteins to the GAG chains, and certain functions are expressed by the free GAG 
chain, but some biological activities also depend upon the presence of the protein 
core in various ways.  
 
Figure 2.7. Illustration of the difference in size and structure of the different PGs. 
Example of a large PG – aggrecan - and a small PG – decorin - found in the ECM. Both the 
size of the core proteins, and the number and kind of GAGs attached, vary amongst the 
different PGs, providing them with them distinct functions. Taken from Alberts, B. et al, 
Molecular biology of the Cell, 3ed (8). 
In the endothelium, PGs are found on the cell surface, in the underlying BMs and in 
the ECM in association with other matrix proteins such as collagen type IV, laminin, 
and fibronectin, as well as in the luminal glycocalyx of the vessels.  
Matrix PGs 
Secreted PGs constitute a major component of the ECM. The ECM is the 
extracellular macromolecular ground substance of connective tissue, and is generally 
composed of proteins like collagens, glycoproteins such as fibronectin, and PGs. It  
has a mechanical role in supporting and maintaining tissue architecture, but can also 
be described as a dynamic meshwork actively regulating critical cellular functions 
such as migration, survival, proliferation and differentiation (34). PGs have been 
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particularly well studied in cartilage in which they constitute over 90 % of the dry 
weight of the tissue (35). The GAGs tend to adopt highly extended conformations 
that occupy a huge volume relative to their mass, and they form gels even at very low 
concentrations. Their high density of negative charges attracts a cloud of cations, 
such as Na+, that are osmotically active, causing large amounts of water to be 
associated with the matrix. This creates a swelling pressure that enables the matrix to 
withstand compressive forces and enable joints and tissue to absorb large pressure 
changes (8). The most common cartilage PG is aggrecan, which binds to HA 
(hyaluronic acid) and a link protein. Although aggrecan is “the cartilage PG”, it is 
also found in other tissues. In the same way other PGs such as decorin, biglycan and 
perlecan are also found in cartilage (36). This illustrates the fact that the intrinsic 
properties of a tissue is not provided by a unique PG, but rather by the unique blend 
of several PGs and their organization in the ECM with other components.  
Given the structural diversity of PG molecules, it would be surprising if their function 
in the ECM were limited to acting as a scaffold and a shock absorber in matrix. The 
GAGs can form gels of varying pore size and charge, and thus serve as selective 
sieves to regulate the traffic of molecules and cells according to size or charge. There 
is evidence that HSPGs such as perlecan has this role in the BM of the kidney 
glomerulus, which filters molecules passing into the urine from the bloodstream (37). 
PGs are thought to play a major part in intracellular signalling and the control of 
growth and differentiation. Matrix PGs can bind and regulate various secreted 
molecules, such as growth factors, cytokines, proteases and protease inhibitors. 
Subendothelial matrix-PGs can bind the LDL constituent apoB and thus be involved 
in the lesion initiation of atherosclerosis (38). Binding to growth factors indicate a 
role in regulating growth and differentiation. Binding of FGF (fibroblast growth 
factor) to HSPGs is required for its activation (39), whereas binding of TGF-β to the 
core protein of several matrix proteins such as decorin inhibits the activity of this 
growth factor (40). PGs also bind to and regulate many inflammatory mediators in 
vitro, suggesting that they serve an important role in modulating inflammatory 
responses in vivo (41). The ability of matrix PGs to bind and then activate or restrain 
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different signalling molecules under different conditions, can affect tissue maturation, 
angiogenesis, invasion and metastasis. 
The matrix PGs comprises the largest class of PGs, and is usually divided in three 
subgroups according to structure and function; the aggrecans/hyalectans, the 
basement membrane PGs and the small leucine rich PGs (SLRP’s) (42).  
Aggrecan is one of the hyalectans; the matrix PGs interacting with hyaluronan and 
lectins. Many aggrecans thus binds to the same hyaluronan chain in matrix, forming 
enormous aggregates, as illustrated in figure 2.8. This PG has a relatively large core 
protein, and over 100 CS or KS GAG-chains. Other hyalectans are versican, brevican 
and neurocan.  
 
Figure 2.8.  Schematic drawing of PG aggregate. The giant aggrecan aggregate, consisting 
of about 100 aggrecan monomers noncovalently bound to a single hyaluronic acid chain 
trough two link proteins that binds both the core protein of the PG and the hyaluronan 
chain. Taken from Alberts, B. et al, Molecular biology of the Cell, 3ed (8). 
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Basement membranes are flexible thin mats of specialized ECM that underlie the 
endothelium, separating it from the underlying connective tissue (figure 2.2). It 
serves structural and filtering roles as well as determining cell polarity, and consists 
of a network of molecules composed primarily of type IV collagen, laminins and 
HSPG. Three PGs are characteristically present in vascular and epithelial basement 
membranes: perlecan, agrin and bamacan (42). The first two primarily carries HS side 
chains, whereas the latter carries primarily CS, and the chimeric structural design of 
these PGs suggests that they may be involved in numerous biological processes (42). 
Perlecan is embedded in the BM of most endothelial cells, and derives its name from 
its appearance as a string of pearls. The molecular structure is illustrated in figure 2.9. 
The protein core of perlecan is ~ 470 kDa, together with numerous N-linked and O-
linked oligosaccharides and 3 HS chains it can reach a molecular weight over 800 
kDa (43). The various modules of perlecan and its HS chains can participate in a 
large number of molecular interactions, binding to growth factors such as FGF2, 
VEGF and PDGF (platelet-derived growth factor), and other protein constituents of 
the BM or cell surfaces (43). Perlecan is also found to carry CS chains. 
 
 
Figure 2.9. Schematic molecular structure of perlecan. The large matrix- PG perlecan 450 
kDa core protein is composed of five domains with distinct properties for interactions with 
other molecules. Three HS, or possibly CS GAG-chains can be attached to the amino-
terminal end. Taken from Segev, A et al. (44).  
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The family of SLRP’s are all characterized by a central domain of leucine-rich 
repeats flanked by small cystein clusters, and further divided into three classes based 
on their protein and genomic organization (see table 1).  These are non-aggregating 
and small KS/DS containing PGs. Decorin is a member of this group, with a protein 
core of ~ 40 kDa and a single CS/DS chains attached. Decorin contribute to the 
proper assembly of connective tissue by interacting with other matrix proteins. 
Decorin interacts with fibrillar collagens, inhibiting fibril formation, as well as 
fibronectin, thrombospondin, the complement component C1q, EGFR (epidermal 
growth factor receptor) and TGF-β. Through the latter interaction decorin is believed 
to function in the control of cell cycle (43;45)(http://www.cmb.lu.se/ctb/). 
 
Figure 2.10. Schematic drawing of the molecular organization of small leucine-rich PG 
decorin. This illustration does not represent the actual sizes of the core proteins or actual 
location of glycosylation sites. Decorin contains one CS or DS chain on the ~ 40 kDa core 
protein. Taken from http://www.glycoforum.gr.jp/science/word/proteoglycan/PGA04E.html  
Cell surface PGs 
All cellular processes that involve molecular interactions at the cell-surface, such as 
cell-matrix, cell-cell and ligand-receptor interactions, are likely to involve PGs. Two 
major families of cell surface PGs have been identified; the syndecans and the 
glypicans. These bind a multitude of growth factors and ECM molecules, and have 
been implicated in several signal transduction pathways that regulate cell 
proliferation and cell shape. They are found on the surface of many cells serving as 
receptors for collagen, fibronectin and other matrix components. Syndecan also acts 
as a co-receptor by binding FGF and presenting it to the FGF receptor proteins on the 
same cell (46). Similarly, β-glycan binds TGF-β and presents it to TGF-β receptors. 
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HSPG binds the pro-inflammatory cytokines TNFα, IL-2, IL-6 and IFNγ and 
syndecan-1 is shown to be able to reduce inflammatory response in toxic shock (41).  
The syndecans are a family of type I transmembrane proteins with an intracellular 
cytoplasmatic domain, while glypicans are attached to discrete cell membrane regions 
by a GPI lipid anchor. Syndecans carry HS chains near the tips of their extracellular 
domains and sometimes also have CS chains attached to the extracellular domains 
near the cell surface. The ectodomain region contains conserved sites for GAG 
attachment, cell interaction, and oligomerization. Numerous ligands are bound via 
their HS chains, and the response to this binding is flavoured by the identity of the 
core protein that bears the HS chains. Each of the syndecan core proteins has a short 
cytoplasmic domain that binds cytosolic regulatory factors. Additionally, all 
syndecans can be shed from the cell surface by proteolytic cleavage at a conserved 
site in the ectodomain near the cell membrane. This shedding is highly regulated and 
can be accelerated by various biological effectors, thereby making it an extremely 
important process in the regulation of syndecan function. The process of ectodomain 
shedding reduces the syndecan at the cell surface, a rapid mechanism to inactivate 
receptor-ligand interaction and signalling. Shedding also converts the cell surface 
HSPG into soluble effectors that may compete for the same ligand or may function in 
a remote location (47).  
PGs are generally considered the most important backbone molecules of the 
glycocalyx, which has been shown to have vasculoprotective effects (19). The 
glycocalyx is situated at the luminal side of all blood vessels and is a negatively 
charged mesh of PGs, membranous glycoproteins, GAGs and associated plasma 
proteins. The volume of this dynamic layer depends on the balance between 
biosynthesis and the enzymatic or shear-dependent shedding of its components 
(figure 2.11). The endothelial glycocalyx is an important determinant of vascular 
permeability, both by size/steric and electrostatic hindrance. It can function as a 
mechanotransducer detecting and amplifying flow-induced shear-forces. The PGs in 
the glycocalyx contribute greatly to its functional importance by the GAG chain 
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variety arising from epimerization, elongation, and sulfation, able to bind a variety of 
plasma derived proteins. This could be receptors and their ligands, enzymes, growth 
factors, cytokines etc. In DM hyperglycemia is associated with reduction of 
glycocalyx dimensions, which is suspected to contribute to endothelial dysfunction, 
and the endothelial glycocalyx is also suggested to be involved in the initiation and 
progression of atherosclerosis (19).   
 
Figure 2.11. Schematic representation of the endothelial glycocalyx, showing its main 
components. Left: The endothelial glycocalyx can be observed in vivo as a red blood cell 
exclusion zone, located on the luminal side of the vascular endothelium. It consists of 
membrane-bound and soluble molecules. Right: Components of the endothelial glycocalyx. 
Bound to the endothelial membrane are PGs, with long unbranched GAG-chains and 
glycoproteins, with short branched carbohydrate side-chains. Incorporated in and on top of 
this grid are plasma and endothelium-derived soluble components, including hyaluronic 
acid and other soluble PGs and various proteins, such as extracellular superoxide dismutase 
(ec-SOD) and antithrombin III (AT III). Together, these components form the endothelial 
glycocalyx that functions as a barrier between blood plasma and the endothelium and exerts 
various roles in plasma and vessel wall homeostasis. Note that this figure is not drawn to 
scale; its purpose is to illustrate glycocalyx composition. Figure and legend taken from 
Reitsma, S. et al, Pflugers Arch 2007(48). 
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Intracellular PGs 
Matrix and cell surface PGs are produced by cells that are engaged in ECM or tissue 
construction. However, several other cells do produce PGs, and particularly cells of 
the immune system and metastasing tumour cells will produce intracellular PGs. 
Intracellular PGs can include endocytosed PGs like glypican-1, nuclear PGs/GAGs 
and  PGs in secretory and storage granules (49). Intracellular PGs interact with 
proteins in different ways; some of which are concentrating and protecting proteins 
organized into granules, assisting transportation of granule-contents to their 
destination, and presenting or releasing proteins (49;50). Serglycin is probably the 
dominating intracellular PG, found in granules of haematopoietic cells, ECs and 
SMCs. Human serglycin is a 17-30 kDa core protein which can potentially carry 8 
HS/CS GAG chains. While the serglycin core protein is conserved, the identity, 
number and sulfation pattern of GAGs may differ between cell types, providing a 
range of different functions (32). Serglycin is stored in granules in mast cells, but is a 
secretory product of macrophages and endothelial cells, which increase during 
inflammation. It execute important functions related to the formation of storage 
granules and the retention of inflammatory mediators inside granules and vesicles 
(32;51), besides being important in the secretory processes of human monocytes (52). 
Secreted serglycin can regulate the activity or transport of partner molecules. Taken 
together, this implies a role for serglycin in the inflammatory process and in relation 
to DM.  
Figure 2.12 illustrates the diverse functions of HSPG, both as intracellular, cell-
surface and extracellular PGs.  
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Figure 2.12. Overview of the functions of HSPGs. HSPGs function as co-receptors for 
growth factors and their receptor tyrosine kinases, which are present either on the same cell 
(a) or on adjacent cells (b). They transport chemokines across cells (c) and present them at 
the cell surface (d). Proteolytic processing leads to the shedding of syndecans and glypicans 
from the cell surface (e), and heparanase cleaves the HS chains (f), liberating bound ligands 
(such as growth factors). Cell-surface HSPGs are actively taken up by endocytosis (g) and 
can recycle back to the surface or be degraded in lysosomes (h). HSPGs also facilitate cell 
adhesion to the extracellular matrix (i) and form bridges to the cytoskeleton (j). Secreted 
HSPGs are involved in the formation of organized extracellular matrices that form 
physiological barriers (k) and sequester growth factors and morphogens for later release 
(l). Serglycin carrying highly sulfated heparin chains is packaged into secretory granules of 
haematopoetic cells (m). Finally, some experiments suggest that HS chains exist in the 
nucleus (n), although their function in this location is unknown. Text and figure taken from 
Bishop, J.R., Nature 2007(50). 
2.4.2 Synthesis 
PGs are produced in the ER and Golgi apparatus. After the ribosomal translation of 
the core protein, except for in KS, GAG synthesis is initiated by sequential addition 
of four monosaccharides donated by UDP-sugars; Xyl, Gal and GlcA into a 
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tetrasaccharide linker, as illustrated in figure 2.13. A xylotransferase will transfer 
xylose (xyl) from UDP-xyl to specific serine residues in the core protein. The xyl-
enriched core protein is transported to the cis-Golgi where galactocyltransferases 
types I and II will add two galactoses (Gal) to the xyl, after which 
glucuronosyltransferase type I adds glucuronic acid (GlcA) completing the GAG-
chain primary linker (8;53).  
 
Figure 2.13.The tetrasaccharide primary linker of GAG-chains. PG synthesis is initiated in 
Golgi by the transfer of a xylose from UDP-xyl to the serine residue in the core protein. 
Addition of two galactose molecules and a molecule of glucuronic acid completes the 
primary linker. The addition of the next saccharide determines whether the GAG chain will 
be CS/DS (addition of GalNAc) or HS/heparin (addition of GlcNAc). From this point 
onward the sugar chain is extended by addition of two alternating monosaccharides; GlcA 
and GlcNAc in HS/heparin, or GlcA and GalNAc in CS/DS. Shown here is KS. Taken from 
http://www.steve.gb.com/science/extracellular_matrix.html 
After completion of the linker saccharide, the addition of the fifth saccharide 
determines whether the GAG chain becomes CS/DS or HS/heparin. In the case of 
HS/heparin GlcNAc is added, in the case of CS/DS GalNAc is added (49;53). Figure 
2.12 illustrate the different steps in the synthesis of these PGs. In KS on the other 
hand, the GAGs are initiated as N-or O-linked oligosaccharides and extended by 
alternating addition of GlcNAc and Gal. Whether GalNAc or GlcNAc is added to the 
primary linker could be determined by several factors; such as the amino acid 
sequence flanking the serine residue on the core protein, and the access of UDP-
sugars and presence of GAG-synthesizing enzymes in the Golgi. Modifications of the 
linker region including phosphorylation, sulfation and epimerisation, has been 
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demonstrated and could be of importance; sulfation of the linker region has been 
observed only in DS/CS, not in heparin/HS (53).  
Following chain polymerization the growing GAG-chain will undergo modifications 
including N-sulfation, epimerization and O-sulfation (31;49;53). These chain 
modifications take place in both the cis- and trans- Golgi, determining the final type 
and functionality of the PG. Epimerization of GlcA into IdoA change CS into DS, 
and the sulfation pattern distinguish HS from the more heavily sulfated heparin. 
Elongation and modification of GAG chains is catalyzed by different sets of enzymes 
in different sub domains of the Golgi apparatus. The chain elongation is probably 
dependent on these modifications; in particular will sulfation determine when chain 
elongation is terminated (53). There is also regional variability to the epimerization 
and sulfation within each GAG chain, giving rise to motifs required for specific 
interaction with growth factors, cytokines, matrix components, enzymes and other 
proteins. In contrast to HS/heparin and CS/DS, hyaluronan is assembled at the cell 
membrane, and is not modified afterwards. As a consequence it has no sulfate groups 
or modifications.  
After synthesis and modifications PGs are transported from the Golgi to their 
destinations: the ECM, the cell surface or intracellular organelles. In endothelial and 
other polarized cells there is also an apical / basolateral sorting of the PGs. 
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Figure 2.14.The different steps in the synthesis of CS, DS, HS and heparin 
glycosaminoglycan chains. Taken from Prydz, K. et.al, J.Cell Sci. 2000 (53).  
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2.5 PGs in hyperglycemia and inflammation 
The synthesis and structure of PGs are shown to change during hyperglycemia, and 
are thought to influence the progression of diabetic complications. In order to 
understand this relationship, it is necessary to study changes in PG expression and 
structure in relation to diabetic conditions such as hyperglycemia and inflammation. 
Changes in PG expression in EC may affect important functions such as cytokine 
signalling, lipoprotein turnover and chemokine regulation, which are all relevant in 
DM. Hyperglycemia has been shown to decrease PG expression in cultured human 
endothelial cells (54).  
DM is regarded as an inflammatory disease, and the endothelium is able to respond to 
inflammatory cytokines trough the binding with matrix and cell-surface PGs. Each 
cytokine bind to a specific cell-surface receptor, and subsequent cascades of 
intracellular signalling then alter cell functions. HSPG are known to bind several 
proinflammatory cytokines, amongst them TNF-α (41). The release of TNF-α and IL-
1 is believed to increase vascular permeability and contribute to the atherosclerotic 
process. Elevated levels of IL-1α and TNF-α has been measured in persons with DM 
(18;29) Inflammatory cytokines (TNF-α) are increased in hyperglycemia in humans 
(55). 
The uptake of lipoproteins is also an important feature of inflammation and the 
development of atherosclerosis. HSPG is important for uptake of lipoproteins, both in 
normal and in pathological lipoprotein metabolism. HS will bind LPL and 
lipoproteins in a complex on the cell surface, making HS important in the 
development of atherosclerosis (31;56). 
Entry of leukocytes into tissues is a key feature of inflammation, and EC HSPG 
expression is required for several stages of this entry process. Endothelial HSPG is 
important in L-selectin binding to neutrophils, in chemokine presentation and in 
chemokine transportation across the endothelium. These roles of HSPG in leukocyte 
entry are illustrated in figure 2.15. Thus, HSPG is important in the inflammatory 
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process of DM (57). Different PGs are, however, observed to have contradictory 
effects, both anti – and pro- atherogenic. Although facilitating lipoprotein uptake and 
monocyte adhesion to the endothelium, increased HSPG in EC have also been 
associated with decreased monocyte binding to subendothelial matrix (24). 
 
Figure 2.15. Role of HS in leukocyte entry into sites of inflammation. In response to 
inflammatory stimuli from cytokines, ECs and resident macrophages in the vascular wall 
will produce both chemokines that attracts leukocytes into tissue, and cytokines that trigger 
the display of selectin luminally on ECs. Endothelial HSPGs act as coreseptors for 
chemokines. PSGL, P-selectin glycoprotein ligand-1; ICAM, intracellular adhesion 
molecule. Taken from Parish,C.R., Nat Immunol 2005 (57). 
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3. Aims 
DM is associated with several micro- and macrovascular complications, and in the 
course of prevention, it is important to obtain a better understanding of the underlying 
mechanisms.  
The endothelium is the prime organ to be exposed to the hyperglycemia of DM, and 
hyperglycemia is identified as a primary causal factor in the development of DM 
complications, and might be responsible for impairment of significant functions of 
the endothelium (12;13). PGs are important components of the vascular tissue, 
influencing arterial properties such as viscoelasticity, permeability, lipid metabolism, 
cell adhesion, proliferation, hemostasis and thrombosis (23;31;35;42;43). 
Endothelial dysfunction is a key component in the pathogenesis of atherosclerosis, 
and hyperglycemia contributes to the chronic inflammation seen in endothelial 
dysfunction. PG structure and composition are altered in atherosclerotic lesions, most 
evident in DM. Increased levels of IL-1α and TNF-α is observed in DM. DM 
associated quantitative and qualitative alterations of PGs are being increasingly 
reported, and are proposed to play an important role in the pathogenesis of diabetic 
complications (54;58;59). Studies have shown that exposing HUVEC (Human 
umbilical cord vein endothelial cells) to IL-1α and TNF-α increase PG synthesis (60) 
and hyperglycemia is also shown to alter the endothelial PG expression (54). 
These studies were initiated to investigate the changes in endothelial PG expression 
during diabetic conditions. ECs were obtained from umbilical cords and cultured in 
vitro to study the response to hyperglycemia and inflammatory conditions. A 
hyperglycemic environment was mimicked both by exposing the cells to high glucose 
or to the glucose metabolite GlcN. Inflammatory conditions were created by exposure 
to each of the pro-inflammatory cytokines IL-1α and TNF-α.  
Quantitative and qualitative effects on cell proliferation, total de novo PG synthesis 
and the individual PGs perlecan and decorin were investigated.   
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Specific aims 
 To study the biological effects of GlcN on primary human endothelial cells 
 Effect on proliferation 
 Effect on total de novo PG biosynthesis and secretion 
 To study the biological effects of hyperglycemia, using high glucose or GlcN on 
primary human endothelial cells 
 Effects on proliferation 
 Effects on total de novo biosynthesis and secretion  
 Effects on PG composition  
 To study the biological effects of inflammation, using IL-1α and TNF-α on 
primary human endothelial cells 
 Effects on proliferation 
 Effects on total de novo biosynthesis and secretion  
 Effect on PG composition  
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4. Methods 
4.1 Human Umbilical Vein Endothelial Cells (HUVEC) 
HUVEC are primary ECs isolated from the vein of human umbilical cord.  
Ethical approval for the use of human ECs from the Human Research Ethical 
Committee was obtained by our collaborators at Rikshospitalet. The use of umbilical 
cords was approved in advance by the mothers (61). 
4.1.1 Isolation of HUVEC from umbilical cord  
HUVEC were enzymatically isolated from infant umbilical cords of normal 
pregnancies using collagenase. This was done under sterile conditions and the cells 
were established as primary cell cultures. This was first done by E. A. Jaffe et al (62). 
The location of the vein of the umbilical cord is illustrated by figure 4.1. 
 
Figure 4.1. Illustration of the 
placenta and the umbilical cord. 
HUVEC were obtained from the vein 
of the umbilical cord. The umbilical 
cord vein is shown in red in this 
figure, transporting oxygen rich 
blood from the mother to the foetus. 
Modified from 
http://dralaamosbah.blogspot.com/ 
 
Procedure: 
1. Umbilical cords were obtained from the local Obstetric and Gynaecology 
division at Rikshospitalet, Oslo, placed in a sterile container filled with cord 
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buffer and kept at 4°C. The cord was stored for a maximum of 3 days before 
processed 
2. Injured parts were removed. Metal cannulas were placed in each end of the 
vein and the vein was then rinsed in PBS (phosphate buffered saline) 
3. 10 ml 0.2 % collagenase was infused into the umbilical vein and incubated in 
37°C for 10 min. 
4. The collagenase solution containing the ECs was flushed from the cord by 
perfusion PBS. 
5. The cells were sedimented at 1500 rpm for 10 min, resuspended in 5 ml fresh 
culture medium and then incubated at 37°C and 0.5 % CO2 in a 25cm2 cell 
culture flask.
Equipment and solutions:
Equipment Additional equipment 
needed 
Solutions 
2 metal cannulas 2 single use syringes 50 
mL 
1XPBS, 50 mL, 
autoclaved 
3 compresses 1 single use syringe 15 
mL 
Cord buffer 
2 small pieces of aluminium 
foil 
1 50 mL centrifuge tube 0.2% collagenase, 10 ml 
4 plastic straps 1 cell flask 25 cm2 Medium 
4 plastic tubes (2-3 cm) Sterile surgical glows  
3 glass vials, 2x200 mL and 
1x100 mL 
Water bath, 37oC  
A sterile tray to work on 1 sterile surgical blade  
All equipment was autoclaved 
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4.1.2 Culturing HUVEC 
HUVECs were grown at 37°C and 0.5% CO2 in plastic bottles or wells of different 
sizes, in complete endothelial basal medium of 7 % FCS (foetal calf serum), and fed 
twice a week.  
Solutions: 
Complete MCDB medium 
Components Volume Final concentration 
MCDB-131 medium Powder for 500 ml  
NaHCO3 0.59 g  
mQ-H2O 500 mL  
FGF 10µg/mL  50 µL 1 ng/mL 
Hydrocortisone 10 mg/ mL 50 µL 1 µg/mL 
EGF 10 µg/mL 500 µL 10 ng/mL 
Gentamicine 50 mg/mL 500 µL 50 µg/mL 
Fungisone 250 µg/mL 500 µL 250 ng/mL 
FCS (heat inactivated) 37.5 mL 7% 
MCDB-131 medium powder and NaHCO3 were dissolved in the water, and the pH was 
adjusted to 7.3  adding 1M HCl or NaOH while stirring. This solution was sterilized by 
filtration and aseptically dispensed into a sterile container before additional sterile 
ingredients was aseptically added.  
HUVECs were split at a 1:3 ratio when 100% confluent, usually once or twice a 
week. This was done by adding a solution of trypsin and EDTA, detaching the cells 
from the plastic and each other. Trypsin is a protease braking down proteins on the 
cell surface needed for adhesion, thereby releasing the cells from the plastic. The 
chelating agent EDTA binds to calcium and prevents joining of cadherins between 
cells. Cadherins are calcium dependent transmembrane proteins important for cell-
cell adhesion, thus EDTA prevents clumping of cells.  
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Procedure: 
1. Trypsin/EDTA solution and complete medium was heated to 37ºC in water 
bath. 
2. The culturing medium was collected and the cells were washed in trypsin 
solution in order to remove FCS remnants. 
3. Cells were incubated in trypsin / EDTA until detached from the plastic and 
each other. When observed in microscope; the cells will get a round shape. 
4. The trypsin was inactivated by adding equal volumes of medium containing 
7% FCS. 
5. The cells were pelleted at 1200 rpm for 3 minutes and re-suspended in a 
desired volume of complete medium, before added to cell culture flasks or 
wells. 
6. The cells were incubated at 37°C and 0.5% CO2.  
4.1.3 Freezing and thawing of cells 
After isolation the cells can be frozen and stored in liquid nitrogen. This was 
performed in the presence of DMSO (dimethyl sulfoxide) to prevent crystal 
formation. The cells were trypsinized, pelleted and resuspended in freezing-medium I. 
An equal volume of freezing-medium II was added drop by drop while stirring 
carefully. The cell suspension was transferred to cool cryovials and put in liquid 
nitrogen for long-term storage.  
When needed, the frozen cells could be removed from the nitrogen tank and thawed 
rapidly in a water bath of 37oC. The thawed cells were carefully mixed with 5 ml 
MCDB-medium and pelleted at 1200 rpm for 3 min to remove the DMSO. The pellet 
was resuspended in the desired volume of culture medium and incubated as 
previously described.  
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Solutions: 
Freezing medium I 
Components Volume Final concentration 
MCDB-medium 2 ml 50% 
FCS (heat inactivated) 2 ml 50% 
 
Freezing medium II 
Components Volume Final concentration 
MCDB-medium 4 ml 80% 
DMSO 1 ml 20% 
 
4.2 General Experimental Outline  
Generally, the cells were grown in 12 wells culture plates for counting, 6 well plates 
or small cell culture flasks for sulfate-labelling and finally cell culture flasks of 
different sizes for Western analysis. The cells were cultured until confluent in 
MCDB-medium with 5.0 mM glucose and 7% FCS 
The cells were exposed to either high glucose (25.0 mM) (54), GlcN (0, 0.1, 1.0, 2.0, 
5.0 or10.0 mM), IL-1α (2 ng / ml) or TNF-α (7 ng / ml)(60). Low glucose (5.0 mM) 
was used as control in all experiments. 
Cell exposures were performed for the indicated time, usually 24 hours. Medium was 
changed to sulfate free RPMI 1640 medium containing 5.0 mM glucose and 2 % FCS 
for all radiolabelling experiments. When exposing to high glucose, glucose was 
added to a total of 25 mM. In experiments not including radiolabelling (i.e Western 
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blotting), MCDB medium of 2 % FCS and 5.0 mM glucose was used. Also here, 
when exposing to high glucose, glucose was added to a total of 25 mM.  
Regarding the experimental outline when collecting data such as cell number, protein 
contents or cpm (counts per minute); each exposure was performed in parallels and 
from each of these, two samples were taken. Thus, these data are based on duplicates 
of parallels. Each experiment was usually performed on cells from umbilical cords 
from at least three different individuals.  
4.3 Cell count 
In order to determine differences in cell growth and viability of the different culturing 
conditions, the cells were stained and counted visually using a hemacytometer 
(Bürker chamber).  
Trypan blue is a stain commonly used in estimating the proportion of viable cells in a 
population. The negatively charged chromophore will react only with damaged cell 
membranes, dying only dead cells. In this way the staining facilitates the visualization 
of the amount of dead and live cells. 
Procedure: 
1. The cells were trypsinized by standard techniques (section 4.1.2) and MCDB-
medium containing 7% serum was added to inactivate the trypsin. The cells 
were dispersed thoroughly by vigorously pipetting the suspension. Equal 
amounts of cell suspension and trypan blue solution (f ex 50 µl of each) was 
mixed and allowed to rest between 5 and 15 minutes. 
2. The cover slip was fastened and a small amount of cell solution was 
transferred to the edges; with the help of capillary forces both chambers were 
filled.  
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3. The hemacytometer was placed on a microscope, and in each of the two 
chambers the number of dead and alive cells in 16 small squares was counted 
twice.  
16 squares contain 0.1 μl solution. The original number of cells can thus be calculated 
taking all dilutions into account: Cells/ml = (average count in 16 squares) x (dilution 
factor) x 104 [chamber conversion factor]. Total cell number = (cells/ml) x original or 
pre-dilution volume. 
Example: (20 cells) x (2) x (104) = 0.4 x 106 cells/ml. This is the contents of cells 
solubilised in trypsin, typically 3 ml in a small cell culturing flask. Then, the total cell 
number is: 0.4 x 106 cells/ml x 3 ml = 1.2 million cells. 
4.4 Labelling with 35S-sulfate  
The GAG-chains of PGs are highly sulfated and 35S-sulfate added to the medium will 
be taken up by the cells and incorporated into newly synthesized PGs. Supplying the 
cells with radioactively labelled sulfate will thus enable us to detect and study the de 
novo synthesis of PGs, without any interference of PGs already present in the cells, 
medium, serum etc. Other molecules containing sulfate will also be labelled, but after 
purification by G-50 fine gel chromatography, PGs have been shown to comprise the 
major part of the labelled macromolecules (63). Thus, the amount of 35S-sulfate 
incorporated into macromolecules is used as a measurement of the amount of PG 
synthesized.  
The cells were grown in MCDB-medium with 7% FCS and 5.0 mM glucose in cell-
culture flasks or wells, until confluent. Because both medium and FCS contained 
sulfate, which will compete with the 35S-sulfate for uptake by cells, the medium was 
changed to sulfate free RPMI 1640 medium during radiolabelling, and the amount of 
serum reduced to 2%. As sulfate and other ingredients could obscure the results, the 
cells should ideally be cultured under serum-free conditions. However, the cells grow 
poorly under such conditions, and the serum concentration is reduced rather than 
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eliminated. The cells were incubated for 24 hours in 0.1 mCi 35S-sulfate/ml medium. 
In some experiments this was increased to 0.2 mCi, in order to increase the labelling 
efficiency.  
After metabolic labelling with 35S-sulfate for 24 hours, the medium and cell fraction 
were harvested as described below. The samples contained both free, unbound 35S-
sulfate and other 35S-labelled macromolecules besides the radio-labelled PGs.  
Unbound 35S-sulfate and other small molecules were removed by gelfiltration, in 
which molecules are separated according to size. Separation of PGs from other 
macromolecules can also be performed by ion-exchange chromatography, where 
molecules are separated according to charge. 
4.5 Harvesting 
After different types of stimulation and radiolabelling, the cells and conditioned 
medium was harvested using Guanidine/Triton X-100 buffer. RIPA buffer was used 
for lysis of cells for Western blotting analysis. Fosfatase inhibitor was added to the 
latter to slow down the proteolysis, defosforylation and denaturation of the cell 
lysate.  
Procedure: 
1. Medium fractions were collected and centrifuged 3 min at 1200 rpm to remove 
cell debris 
2. Cells were carefully washed  in 37°C PBS to remove rests of medium 
3. The cells were lysed for 10-15 min before carefully mixed and harvested  
4. Samples were purified and further analysed, or frozen. 
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Solutions: 
Guanidine / Triton X-100 harvesting buffer for 35S-labelled cells 
600 ml 4M Guanidine HCl in 0.1M acetate buffer with 2% Triton X-100, pH 6.0 
Components Volume Final concentration 
Guanidine HCl 229.27 g 4M 
Triton X-100 12 ml 2 % 
0.1M Acetatebuffer pH 6,5 Up to 600 ml 0.1M 
Guanidine HCl was added to the Ac buffer and the volume adjusted to 600 mL. Then the 
solution was rinsed while stirring with charcoal over night, and then filtered twice before 
Triton X-100 was added to a final concentration of 2 %. PH was adjusted to 6.0. 
RIPA lysis buffer – for cell harvesting before Western blotting analyses.  
Components Final concentration 
Tris-HCl pH 7.4 50 mM 
NaCl 150 mM 
Triton X-100 1 % 
SDS 1 % 
 Na-Deoxycholate  1 % 
EDTA 10 mM 
Na4PO2O7 Sodium pyrophosphate  10 mM 
Fosfatase-inhibitor tablet (freshly added) 1 tabl. 
 
4.6 Scintillation counting 
The amount of radio-labelled molecules in a metabolically labelled sample can be 
estimated using a liquid scintillation counter, which measures radiation from β-
emitting nuclides such as 35S.  
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Radio-labelled samples were mixed with a liquid scintillation ‘cocktail’ of solvent, 
emulsifier and Flurophore. The kinetic energy of the β-particles is absorbed by 
solvent molecules, and the energy of these excited molecules is emitted as UV-light. 
The UV-light is absorbed by Fluor, which in turn emits blue light upon returning to 
ground state. The samples were placed in small transparent vials loaded into a liquid 
scintillation counter, where light flashes emitted per minute are counted. In this way, 
each beta emission results in a pulse of light, and the amount of light emitted will 
reflect the amount of radioactivity of the sample. Each sample was counted for three 
minutes, and measured as cpm. 
4.7 Protein quantitation  
Protein measurement of cell lysate is a way of monitoring the cell growth and 
proliferation. When taken together with cell counts, protein quantification can give 
information about cell growth. Increasing protein concentrations could indicate either 
hyperplasia (increasing number of cells) or hypertrophy (increasing size of the cells).  
Determination of the protein concentration of a solution can be done using the 
Uptima BC Assay protein quantitation kit. This method is based on the reduction of 
Cu2+ to Cu+ by protein peptidic bonds. This reduction can be quantified by adding 
bicinchoinic acid which in the presence of Cu+ forms a coloured complex with 
absorption maxima at 562 nm. The absorbance is directly proportional to the protein 
concentration, which can be calculated using a standard curve. The method is 
modified after Paul Smith et al (64). 
Procedure: 
The cells were cultured in wells or flasks as described and stimulated as required 
before harvested and analyzed. Only cell lysates were analysed for protein content. 
1. Cells were harvested as described for the experiment in question. 35S-labelled 
cell fractions were subjected to Sephadex G-50 fine chromatography. 
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2. Standards were made out of a BSA stock solution of 2 mg protein / ml diluted 
in the same buffer as in the cell-samples. The stock is diluted 1:10 sequentially 
for 11 times achieving a standard curve of 12 different concentrations of 
protein (including one blank).  
3. A+B solution was made from 2 % assay reagent A and 98 % assay reagent B, 
in volumes appropriate to the number of samples being analyzed.  
4. 25 μl of sample or standard were added in doublets to a 96-well microtitrer 
plate, and 200 μl of A+B solution was added to each well. The samples are re-
suspended thoroughly before application. 
5. The plate was gently stirred for 2 min, and then incubated at 37ºC for about 30 
min (depending on the colour development). Bubbles were poked a hole in.  
6. The absorbance was measured at 562 nm using the Titertec multiscan PLUS 
spectrophotometer.  
7. A standard curve was created plotting the absorbance (Y-axis) versus their 
corresponding known protein concentrations (X-axis), and the concentrations 
of the unknown samples was calculated from this. Taking dilutions into 
account, the original protein concentration was calculated.  
4.8 Sample purification 
In order to study the PGs, they need to be purified to different degree, depending on 
the methods of further analyses.  
4.8.1 Gelfiltration– Sephadex G-50 fine  
After radiolabelling, the samples will contain both free 35S-sulfate and 35S-sulfate 
incorporated in macromolecules; which thus can be separated according to size using 
gelfiltration.  
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Gelfiltration separates proteins according to molecular size. This separation is 
achieved using a porous matrix to which the molecules, for steric reasons, have 
different degrees of access; smaller molecules have greater access than larger 
molecules. The matrix is packed in a column, the sample mixture added, and the 
separation is achieved by passing an aqueous buffer through the column and 
sampling eluted fractions. The size of the molecules separated will depend on the 
matrix chosen; Sephadex G-50 fine will separate proteins of 0.5-10 kDa. Small 
molecules like unbound sulfate will penetrate the matrix and will be eluted in 
decreasing order of size. Larger protein molecules, like PGs, will be confined in the 
volume outside the matrix beads and will be swept through the column by the mobile 
phase and be eluted first.  
Procedure: 
1. Sephadex G-50 fine powder was swollen into a gel over night in the buffer of 
choice, we used 0.05M NaCl 0.05M, Tris-HCl pH 8,0 
2. Columns were made of 10mL pipettes cut at the 7 mL mark and filled with 
glass wool in the bottom. Each column was filled with 4 ml of Sephadex G-50 
fine gel. 
3. 1 ml of sample was applied. 
4. The first 1 ml of elute was discarded. 
5. PGs and other macromolecules were eluted in the void volume with 1.5 ml 
buffer, and collected. Free 35S remained associated with the column, which 
was discarded. 
6. Aliquots of this elute (2x50µL) was counted for radioactivity using the 
scintillation counter. 
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Solutions: 
500 ml G50-fine buffer: 0.05M NaCl in 0.05M Tris-HCl pH 8.0 
Components Volume Final concentration 
1.0M Tris 25 ml 0.05M 
NaCl 1.461 g 0.05M 
mQ-H2O Up to 500 ml  
pH was adjusted to 8.0 adding 5.0M HCl 
Sephadex G50-fine solution 
Components Volume 
Sephadex G-50 fine powder 10 teaspoons 
0.05M NaCl in 0.05M Tris-HCl, pH 8.0 500 ml 
The solution was swollen overnight 
 
4.8.2 DEAE anion-exchange chromatography 
Ion-exchange chromatography separates molecules according to charge. DEAE 
(Diethylaminoethyl) is a weak anion-exchanger, binding the highly negative charged 
PGs by ionic bonds. Slightly negative, neutral or positively charged molecules will 
not bind and can be washed out. Then, the PGs can be eluted by high salt 
concentration (2M NaCl). Thus, by this method PGs are separated from other 
macromolecules according to charge (65). 
Procedure: 
1. The ethanol in which the DEAE was solved was removed by washing 
twice in equal amount of low salt Tris buffer (0.15M NaCl 0.05M Tris-HCl 
pH 8.0). The mixture was shaken thoroughly, spinned down in centrifuge 
and the supernatant was removed before solved in equal amount of buffer. 
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2. 600 μl washed DEAE was added to every sample (about 1.5 mL) and 
mixed 5 min on shaker before spinned down by centrifugation. Negatively 
charged proteins as PGs will bind to the DEAE, and the supernatant 
containing other macromolecules can be removed.   
3. The sediment was washed twice in Tris buffer of slightly higher salt (0.3M 
NaCl/0.05M Tris), eluting weakly negatively charged proteins like BSA. 
4. Finally the PGs were eluted in high salt, in which the ionic bonds between 
the DEAE and PGs are broken, by washing three times in 500μl 2M NaCl/ 
0.05M Tris (alternatively 2M NH4HCO3) and collecting the supernatant 
containing the PGs.  
 
Low salt Tris buffer: 0.15 M NaCl in 0.05M Tris-HCl pH 8.0 
Components Volume Final concentration 
1.0M Tris buffer 25 ml 0.05M 
4.0M NaCl 18.75 ml 0.15M 
mQ-H2O Up to 500 ml  
pH was adjusted with 1M HCl to 8.0 
Medium salt Tris buffer: 0.3 M NaCl in 0.05 M Tris pH 8.0 
Components Volume Final concentration 
1.0M Tris buffer 25 ml 0.05M 
4.0M NaCl 37.5 ml 0.3M 
mQ-H2O Up to 500 ml  
pH was adjusted with 1M HCl to 8.0 
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High salt Tris buffer: 2 M NaCl in 0.05 M Tris-HCl pH 8 
Components Volume Final concentration 
1.0M Tris buffer 25 ml 0.05M 
NaCl 58.44 g 2.0M 
mQ-H2O Up to 500 ml  
pH was adjusted with 1M HCl to 8.0 
4.9 Concentrating the samples  
In order to apply enough material per well when performing electrophoresis, the 
samples were concentrated prior to mounting. This was done by different methods, 
depending on the sample volume and prior treatment. Vacuum centrifuge and freeze-
dryer could be used when the samples were not eluted with salt (DEAE). Freeze-
drying is better suited for large volumes, but could be harsh treatment. Concentration 
on microcon is suited for small samples eluted in salt, as the samples in this way also 
are desalted.  
In SDS-PAGE of the radio-labelled material samples of equal protein content and ~ 
10 000 cpm were mounted in each well. For Western blotting, cell lysate or media 
equivalent to at least one small culturing flask was used per well. 
4.10 GAG-depolymerisation 
4.10.1 Chondroitinase ABC  
Polysaccharide-lyases are a class of enzymes especially suited for GAG- and PG 
analyses, as they cleave specific glycosidic bonds and facilitate a depolymerisation of 
polysaccharides (GAG-chains). Choindroitin lyases are prokaryotic GAG-degrading 
lyases that will depolymerise GAG by an elimination mechanism. (Eucaryotic 
enzymes act by hydrolysis). There are two classes of choindroitin lyases, 
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chondroitinase AC and ABC. The latter will act on CS-A, CS-C and DS (CS-B), as 
illustrated by figure 4.2.   
 
Figure 4.2. Illustration of the cleavage action of chondroitinase ABC, which will act on 
both chondroitin sulfate A and C, as well as DS (CS-B). 
Chondroitinase ABC (cABC) was used for identification of CS/DS-PGs. Optimal 
conditions for this enzyme is Tris-HCl/NaAc buffer, 0.05 M and incubation at 37ºC. 
It will depolymerise CS and DS GAG-chains at pH 8 into disaccharides, without 
affecting HS.   
Procedure: 
1. 0.01U of cABC enzyme was added to each sample. 
2. 10x cABC-buffer was added until 1x. 
3. Samples were incubated over night at 37°C 
Solutions: 
10 x c-ABC buffer- 0.5M Tris-HCl pH 8.0, 0.5 M sodium acetate, 10 mL 
Components Volume Final concentration 
1M Tris pH 8.0 5 ml 0.5M 
NaAc·3H2O 0.68 g 0.5M 
mQ-H2O Until 10 ml  
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4.10.2 HNO2 – Cleavage of N-sulfated GAGs  
All GAG-chains consists of an amino sugar in every second position, which normally 
are N-acetylated (GalNAc in CS and DS, GlcNAc in HS, heparin, hyaluronic acid). 
In heparin and heparan sulfate a high percentage of the N-acetyl substituents are 
replaced by N-sulfate groups. N-sulfated glucosamines (GlcNSO3) are sites that are 
unique in their susceptibility to facilitate cleavage by nitrous acid at room 
temperature and low pH (~1.5). Thus, when heparins or heparan sulfates are treated 
with nitrous acid, they are specifically cleaved into fragments with ranges of 
molecular weight depending on the distribution of the GlcNSO3 residues in the chain. 
N-acetylated amino sugars are not affected by this treatment, and only HSPG GAG-
chains will be cleaved (66). 
 
Figure 4.3. Illustration of heparin / heparan sulfate and the location of the target site of 
nitrous cleavage.  The location of the possible N-sulfate is unique for heparin/HS and is the 
target of nitrous cleavage at low pH, as indicated by the red arrow. Adapted from 
http://courses.cm.utexas.edu.  
Procedure: 
1. Equal volumes of sample and HNO2 was mixed and incubated for 10 minutes 
at room temperature. 
2. The reaction was stopped by increasing the pH to 8.5 by adding Na2CO3.  
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Solutions: 
0.5 M H2SO4 50 mL 
Components Volume Final concentration 
H2SO4 1.33 g 0.5M 
mQ-H2O Up to 50 mL  
 
0.5 M Ba(NO2)2, 10 mL, made fresh for each experiment 
Components Volume Final concentration 
Ba(NO2)2 ·H2O 1.24 g 0.5M 
mQ-H2O Up to 10 mL  
 
HNO2 pH 1.5 
Components Volume 
0.5 M H2SO4 Equal volumes 
0.5M Ba(NO2)2 Equal volumes 
Equal volumes of ice cold reagents was mixed, centrifuged and the supernatant which 
comprises the HNO2collected. This reagent must be stored on ice, and must be used 
immediately. H2SO4 + Ba(NO2)2 → 2HNO2 + BaSO4(s) 
2 M Na2CO3  
Components Volume Final concentration 
Na2CO3 2.12 g   2.0M 
mQ-H2O Up to 10 mL  
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4.11 SDS – PAGE sodium dodecyl sulfate 
polyacrylamide gel electrophoresis 
Generally, gelelectrophoresis is a technique in which charged molecules, such as 
protein or DNA, are separated according to physical properties as they are forced 
through a gel by an electrical current. Proteins are commonly separated using Poly 
Acrylamide Gel Electrophoresis (PAGE) to characterize individual proteins in a 
complex sample or to examine multiple proteins within a single sample. PAGE can 
be used as a preparative tool to obtain a pure protein sample, or as an analytical tool 
to provide information on the mass, charge, purity or presence of a protein. Several 
forms of PAGE exist and can provide different types of information about the 
protein(s). SDS-PAGE, the most widely used electrophoresis technique, separates 
proteins primarily by mass. The size and mass of the protein will be inversely related 
to the degree of migration in the gel. For PGs the GAG-chains also affects the 
migration. Proteins can also be separated in non-denaturating conditions; not 
containing SDS. 
Polyacrylamide gels are formed from the polymerization of acrylamide and bis (N,N-
methylenebisacrylamide) in the presence of ammonium persulfate and TEMED 
(N,N,N,N'-tetramethylenediamine). The size of the pores created in the gel is 
inversely related to the amount of acrylamide used. Gels with a low percentage of 
acrylamide are typically used to resolve large proteins and high percentage gels are 
used to resolve small proteins. A gradient gel allows separation of a mixture of 
proteins with a greater molecular weight range than a gel with a fixed acrylamide 
concentration.  
The samples were treated with sample buffer containing the detergent SDS prior to 
application on the gel. This ionic detergent denatures the proteins and binds tightly to 
the uncoiled molecule. Because of the sulfate groups, the SDS molecules mask the 
intrinsic charge of the protein and create a relatively uniform negative charge 
distribution. When an electric current is applied, all proteins will migrate through the 
gel toward the anode, which is placed at the bottom of the gel. Because of the 
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uniform charge:mass ratio created by SDS-binding, the SDS-PAGE gel then 
separates the proteins primarily according to size. Proteins with less mass travel more 
quickly through the gel than those with greater. Protein molecular weights can be 
estimated by running standard proteins of known molecular weights in separate lanes 
of the same gel. 
In addition to SDS, the sample buffer also contains 2-β-mercaptoethanol 
(alternatively DDT) for further denaturation (reduction of disulphide bridges), 
glycerol (to increase loading efficiency) and bromophenol blue-marker dye. Boiling 
or heating is also a common way of denaturating the proteins, but PGs tends to 
aggregate so heating is not used here.  
Procedure: 
1. In order to be detectable, the samples must contain a quantity of PGs 
equivalent to a minimum of 10 000 cpm in each radio-labelled sample, and it 
is often necessary to concentrate the samples prior to loading.  
2. Loading buffer containing glycerol, bromophenol blue marker dye, 
denaturating SDS and 2-mercaptoethanol was added to the samples, and 
incubated in room temperature for 15 min. 
3. The gel was mounted in the electrophoresis apparatus and running buffer was 
added to the top and bottom reservoirs.  
4. Samples and standards were carefully loaded in a predetermined order to the 
wells, after “rinsing” the well with a pipette.  
5. The apparatus was attached to an electric power supply and a voltage of 110V 
was applied to the gel until the bromophenol blue reached the bottom of the 
gel, after approximately 2 hours. 
6. As soon as the power was turned off, the gel was treated with fixing solution 
to prevent diffusion of proteins.  
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7. Gels containing radio-labelled samples were fixed, treated with amplifier, 
dried and subjected to autoradiography. Alternatively, the gel was subjected to 
electroblotting and analysed further by Western blotting 
Solutions: 
4x Loading buffer, 10 ml 
Components Volume Final concentration 
0.1M Tris buffer pH 6,5 2.5 ml 0.025 mM 
Glycerol 4.0 ml 40 % 
SDS 0.8 g 0.08 % (w/v) 
Bromphenol blue 1.0 ml 10% 
2-mercaptoethanol 1.0 ml 10% 
mQ-H2O Up to 10.0 ml  
 
10x Running buffer, 1000 ml 
Components Volume 
Tris base 29.0 g 
Glycin 144.0 g 
SDS 10.0 g 
mQ-H2O Up to 1000 ml 
 
1x Running buffer  
Components Volume Final concentration 
10x running buffer 100 ml 1x 
mQ-H2O 900ml  
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Fixing solution 
Components Volume Final concentration 
Isopropanol 200 ml 25% 
Acetic acid, glacial 80 ml 10% 
mQ-H2O 520 ml 65% 
 
Drying of SDS-PAGE gel 
Before autoradiography the radio-labelled SDS-PAGE gel must be dried. After 
removing the gel from the electrophoresis apparatus, the gel was incubated for 30 
min in fixing solution, then 15 min in amplifier. The gel was then put on a filter paper 
with protective plastic foil on top, and placed on the gel dryer. The lid was tightly 
closed with suction and heated to 70°C for about two hours. The dry gel attached to 
the filter is then removed from the dryer, plastic removed, and ready for 
autoradiography. 
Autoradiography 
Gels containing radioactive material were subjected to autoradiography. The dried gel 
was placed on a film in -70°C for about 7 days, depending on the amount of 
radioactivity in the samples, and then developed. After development, the radioactivity 
was observed as dark regions on the film.  
Generally, in SDS-PAGE, PGs are visualized as smears of high molecular size, in 
contrast to the distinct bands of proteins. This is due to the heterogeneity in PG size, 
caused by the variation in size, number and composition of the GAG chains attached. 
The intensity of the bands is generally lower in the cell lysate than in the medium, 
indicating that the majority of the PGs are secreted.  
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4.12 Western blotting 
SDS-PAGE is useful in separating PGs, detecting the presence of PGs of different 
sizes and distinguishing between CS and HS-PGs. However, in order to detect 
individual proteins or PGs from a mixture, we can use the technique Western blotting, 
where the PGs are electroblotted from the SDS-PAGE gel to a membrane. Then 
immuno-staining is performed in order to visualize specific proteins bound to the 
membrane.  
Preparation of the samples separated by SDS-PAGE differ as they can be reduced 
and/or denaturated. As the epitope1 may reside within the 3D conformation of the 
protein, the samples usually are denaturated and the proteins separated on a reducing 
SDS-PAGE gel. Alternatively, proteins can be separated both under non-denaturating 
(no SDS) and/or non-reducing (no β-mercaptoethanol) conditions, depending on the 
epitope.  
After separation on SDS-PAGE, proteins were transferred from the gel to a PVDF 
(polyvinylidene fluoridine) blotting membrane using BIORAD Criterion blotter 
system. Wet transfer was performed, as recommended for large proteins.  
The membrane can be probed for specific proteins using antibodies. Blocking the 
membrane in non-fat milk, BSA or another unrelated protein prior to antibody-
incubation prevents non-specific binding of the antibodies to the membrane. Then the 
membrane is exposed to an unlabeled antibody (Ab) specific for the target protein. 
The membrane is washed several times in TBST to remove excess antibody. This 
washing solution contains a detergent (tween 20) and high salt that eliminates non-
specific binding to the membrane through hydrophobic or ionic interactions.  
The Ab bound to the membrane is detected when binding to a secondary Ab coupled 
to horseradish peroxidase (HRP), followed by enhanced chemiluminiscence (ECL). 
                                              
1 antigenic determinant , portion of protein recognised by the antibody 
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After incubation and carefully washing away unbound secondary antibody, the 
Western blot is ready for detection of the labelled probes. The HRP-linked secondary 
antibody is used in conjunction with a chemiluminescent detection method. A 
substrate of HRP is added and the formation of a luminescence is catalyzed. The 
amount of luminescence produced is proportional to the amount of protein on the 
membrane, and can be detected by exposing to a photographic film. Thus, only the 
proteins immuno-stained will be visualized. From the bands on the film you can 
determine the size of the protein relative to the standard, or amount of immunostained 
protein relative to other bands. 
Procedure: 
1. SDS-PAGE.  
The samples were denaturated and the PGs were separated according to size 
on a reducing 4-20 % precast SDS-PAGE gel, as described in section 4.11. 
The amount of protein loaded in each well corresponded to the amount of one 
confluent 25 cm2 cell-culturing flask.  
2. Electro-blotting 
The transfer of proteins from the gel on to a solid support using electricity is 
referred to as electroblotting. The gel was removed from the electrophoresis 
apparatus and equilibrated for 15 min in blotting-buffer to remove SDS-
remnants. The proteins were electroblotted from the gel to a membrane using 
wet transfer. PVDF-membrane and filter papers were cut to cover the gel. The 
membrane was rehydrated by soaking in methanol for 15 seconds, then rinsed 
for 2 min in milliQwater and equilibrated for 10 minutes in blotting buffer. 
Whatman filter-papers and fibre pads was soaked in cold transfer buffer. Then 
gel, membrane, filter papers and fibre pads was placed in the cassette 
according to the instructions of the distributor, and put in the blotting tank. 
Care is taken to remove any air bubbles. A cooling agent and a stir bar were 
added, and the tank was placed on top of a magnetic stirrer, filled with blotting 
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buffer and set at 1,0A for two hours. This high current creates a lot of heat, and 
the cooling agent is renewed when needed, after approx 1 hour. 
3. Blocking 
In order to prevent non-specific binding of the antibodies, the membrane was 
blocked prior to immuno-staining. The membrane was agitated in non-fat milk 
or BSA (depending on the primary antibody) for 1 hour at room temperature. 
4. Immunostaining  
The membrane was incubated in antibody/TBST-solution at 4ºC over night at 
an agitator. The antibody-solution can be reused if always kept at low 
temperature. Unbound antibodies are removed by washing 6x 5 minutes in 
TBST.  
A HRP-linked secondary antibody recognizing the primary antibody is diluted 
in TBST. The membrane is incubated in this solution for 1 hour at room 
temperature, before removing unbound probes in 6x 5 minutes TBST. 
5. Development 
The HRP-enzyme will convert the luminol of the ECL to a light-releasing 
substance, and this light is detected as dark areas on a film. ECL, ECL plus or 
ECL advanced solution was prepared and the membrane was incubated for the 
recommended period of time. The membrane was then transferred to a cassette 
and developed using HyperfilmTM MP and Curix 60 AGFA developer. 
6. Stripping and re-probing 
The probes bound to the membrane can be stripped off before re-probing the 
membrane with another antibody. This is done by washing 5 min in milli-Q 
H2O, blocking buffer, milli-Q H2O, and then 10 min in 2M NaOH, 5 min in 
milli-Q H2O, and 15 min TBST. Finally blocking for 1 hour and rinsing for15 
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minutes in TBST, before incubating with another antibody using the same 
procedure.  
Solutions: 
10x Transfer buffer pH 7.4, 1000 ml 
Components Volume 
Tris-HCl 39.4 g 
Glycin 143 g 
mQ-H2O Up to 1000 ml 
pH was adjusted to 7,4 with 1.0 M HCl or NaOH 
1x Transfer buffer 
Components Volume Final Concentration 
Methanol 200 ml 20 % 
10x transfer buffer 100 ml 1x 
mQ-H2O 700 ml  
 
10x TBS pH 7.5, 1000 ml 
Components Volume 
Tris base 24.22 g 
NaCl 80.15 g 
1M HCl 38 ml 
mQ-H2O Up to 1000 ml 
After adding about 800 ml mQ-H2O, the pH was adjusted to 7,5 using 10M HCl (~50 mL), 
before adding mQ-H2O up to 1000 ml. 10x TBS was stored at 4ºC. 
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TBST 
Components Volume Final Concentration 
10x TBS 200 ml 1x 
Tween 20 2 ml 1% 
mQ-H2O Up to 2000 ml  
 
Blocking buffer 
Components Volume Final Concentration 
TBST 200 ml 0.1% Tween 20 
Dried milk 10 g 5 % 
The blocking buffer was used immediately or stored in refrigerator for a few days 
4.13 Statistical analysis 
In this section we provide a brief introduction to concepts of statistical analysis 
relevant in this work. We then proceed by describing the typical experiments 
performed and the assumptions we have made to give an analysis of the results 
presented in this thesis. 
Introduction 
A normal distribution N(μ, σ) is described by the two parameters, the mean  μ and  
the standard deviation σ. Typically these two parameters are unknown, and needs to 
be estimated. Let {Xi} be a random sample of the normal distribution, consisting of n 
measurements. Then the estimate of the mean X is given by: 
∑
=
=
n
i
iXn
X
1
,1       (1) 
And the estimate of the standard deviation SD by 
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The estimate of the mean follows a normal distribution as well, with a standard 
deviation that is termed the standard error. The estimate of the standard error SE, 
given by 
nSDSE /=       (3) 
is inversely proportional to the square-root of the number of measurements n. About 
95 % of all estimates of the mean X  are within two standard errors SE of the mean μ. 
The estimated standard error therefore gives an indication of how accurate the 
estimated mean is, and should be taken into account when comparing the mean 
values of different populations.  
When taking the ratio Z = X/Y between two means X and Y , with corresponding 
standard errors SE(X) and SE(Y ), the standard error of the ratio is given by 
Y
YSE
X
XSE
Y
XZSE )()()( +=     (4) 
Experiments and assumptions 
In order to get statistically significant results one would typically need a larger 
number of measurements than what we have performed in this work. Nevertheless, 
we provide a statistical analysis to assess the results in a qualitative fashion. In this 
work the HUVEC of several individuals were exerted to different exposures. The 
measurement of one individual at a given exposure was typically composed of two 
parallel samples of cells grown in two parallels. We take the mean of these four 
samples to be one measurement of the individual. There is an error associated with 
each such measurement, and for a thorough statistical analysis one should include this 
error in the analysis. However, for simplicity we disregard this error. All experiments 
contain a control, in which only low glucose has been given. To better compare the 
results between different individuals, we first scale the results of a given individual 
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(at each exposure) with the control of the same individual. In the figures included in 
this work, we present the means of these scaled measurements and their 
corresponding standard errors, using Eq. (1) and Eq. (3) respectively. All results are 
presented as percentages of the control. Note that in some cases we also present the 
ratios between the results of different experiments. The corresponding standard error 
is calculated via Eq. (4). 
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5. Results 
DM is associated both with hyperglycemia and atherosclerotic chronic inflammation 
of the vessels. The endothelium is the prime organ to be exposed to hyperglycemia 
and is one of the main targets of diabetic complications. PGs are important 
components of the healthy endothelium, and are also involved in a number of 
processes important to the development of DM and atherosclerosis. In this way, 
changes in PG expression can be linked to the development of diabetic complications. 
In order to study these changes, we mimicked the diabetic conditions by exposing 
ECs to a hyperglycaemic environment, or to pro-inflammatory cytokines, and studied 
the effects on PG expression. 
General comments 
All experiments were performed on primary HUVECs isolated from different donors, 
carrying distinct qualities. Like other studies performed on HUVEC, we experienced 
varying results from the different donors (61;67). To be able to compare the results of 
the different individuals, all results were presented as percent of the control. 
The cells were grown in complete MCDB 131 culturing medium containing 5,0 mM 
glucose and 7 % FCS, referred to as “MCDB- medium”, unless otherwise noted (see 
section 4.1.2.) and used for experiments when in passage 2-4. In all experiments 
exposures were performed with cells cultured in only 2% FCS, in order to reduce the 
level of cold sulfate, and to create identical culturing conditions for cells later 
compared. All data were based on cells from several, usually three, individuals. Each 
experiment was performed in parallels, and duplicates of measurements were taken 
from each parallel.  
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5.1 Effect of hyperglycemia on PG synthesis 
In order to investigate the role of PGs in DM, HUVECs were exposed to 
hyperglycemic conditions. The effect of hyperglycemia on PG synthesis was 
investigated in two ways; both through direct exposure to high concentration of sugar 
(25 mM glucose), as well as by stimulating the hexosamine pathway by adding the 
glucose metabolite GlcN. High levels of sugar increase the concentration of glucose-
metabolites in the cells and increase the flux trough many metabolic pathways. High 
levels of glucose will increase the level of the metabolite GlcN (25), and GlcN will 
increase the flux trough the hexosamine pathway (25).  
5.1.1 Effect of GlcN on HUVEC 
The glucose metabolite GlcN will bypass the rate limiting GFAT enzyme of the 
hexosamine pathway. Increased flux trough this pathway is thought to affect PG 
synthesis by increasing the level of UDP-GlcN. The effect of GlcN on HUVEC was 
investigated trough the effects on proliferation and expression of 35S-macromolecules 
and 35S-PGs.  
Effect of GlcN on HUVEC proliferation 
As we had no previous experience in exposing HUVEC to GlcN; the appropriate 
dose and time of stimulation had to be established. The effect of GlcN on HUVEC 
proliferation was investigated by exposing HUVEC to different concentrations of 
GlcN. This effect was further investigated as a function of exposure time.  
GlcN dose-response 
The effect of GlcN on cell proliferation was to be studied. The relation between the 
number of cells and the protein concentrations was investigated to assess whether the 
protein content was a suitable measure for cell proliferation.  
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HUVECs from three cell cultures were seeded onto 12-wells cell culture plates and 
grown in MCDB medium until confluent. A 24 hour exposure to parallels of 0, 0.1, 
1.0, 2.0, 5.0 and 10.0 mM GlcN was performed in sulfate free RPMI 1640 medium 
with 2% FCS. Cells were dissolved by trypsin treatment, prior to trypan blue staining, 
and counted as doublets on a hemacytometer in a microscope.   
Cells from the same three different individuals were also exposed in parallels to 
different concentrations of GlcN, and the corresponding protein concentrations were 
measured to assess the effect on cell proliferation. Cells were seeded onto 6-well 
culture plates and grown in MCDB medium until confluent. A 24 hour exposure to 0, 
0.1, 1.0, 2.0, 5.0 and 10.0 mM GlcN was performed in sulfate free RPMI 1640 
medium with 2% FCS. Cells were harvested in Guanidine/Triton X-100 and samples 
purified by gelfiltration, prior to the protein measurements presented in figure 5.1, as 
percent of control.  
 
Figure 5.1. Protein concentration in HUVEC exposed to different concentrations of GlcN. 
Proliferation of HUVEC cultured for 24 hours in GlcN and sulfate free RPMI 1640 medium 
with 2 % FCS. Cells was harvested in Guanidine / Triton X-100 and purified by gel filtration 
before protein determination. The results are based on doublets of parallels from three 
different donors, and presented as % of control with error bars.  
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No differences in protein content were observed after HUVEC exposure to different 
amounts of GlcN, except a possible reduction at 10.0 mM. GlcN concentrations up to 
10.0 mM do not seem to affect HUVEC proliferation using this parameter. There was 
a stable relationship between number of cells and protein concentration until 
exposure to 1.0 mM GlcN (results not shown). At concentrations above 1.0 mM 
cellular effects were observed, such as vulnerability to trypsin treatment. As a 
consequence, GlcN concentrations above 1.0 mM were not used in later experiments, 
and protein could hence be utilized as a measurement for cell viability for GlcN 
concentrations of 1.0 mM and below. 
GlcN time-response 
To determine the necessary exposure time in order to detect effects of GlcN on 
proliferation, parallels of  HUVECs from three individuals were exposed to 1.0 mM 
GlcN for 0, 24, 48 and 72 hours. Proliferation was assessed by protein measurements.  
Cells were grown to confluence in 6-well plates, before changing the culturing 
conditions to sulphate-free RPMI 1640 medium with 2% FCS. The cells were 
exposed to 1.0 mM GlcN for 0, 24, 48 and 72 hours respectively, prior to harvesting 
and gel filtration purification of the samples.  
A slight increase in protein content was observed with increasing incubation time, as 
can be seen in figure 5.2. This increase in protein concentrations suggests a continued 
cell proliferation along with increasing time, as expected for healthy cells. The cell 
viability in 1,0 mM GlcN was clearly not affected during the course of the 
experiment.   
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Figure 5.2. Protein concentration in HUVEC in 1,0 mM GlcN over time. Cell viability in 
HUVEC exposed to 1.0 mM GlcN for 0, 24, 48 and 72 hours in sulfate free medium 
containing 2 % FCS. Cells were harvested in Guanidine/Triton X-100 and samples purified 
by gelfiltration before protein concentrations were determined. The data are based on 
doublets of parallels from three experiments, and presented as % of control with error bars.    
Effect of GlcN on 35S-macromolecules in HUVEC 
The effect of different concentrations of GlcN on the de novo synthesis of 35S-
macromolecules in HUVEC was investigated exposing HUVEC to different 
concentrations of GlcN. This effect was further investigated in relation to exposure 
time. 
GlcN dose-response 
Parallels of HUVECs from the same three individuals as used for cell count and 
protein measurements were exposed to different GlcN concentrations during 
metabolic labelling with 35S-sulfate. The corresponding de novo synthesis of 35S-
macromolecules was measured.   
HUVECs were seeded onto 6-wells culture plates and grown in MCDB medium until 
confluent. A 24 hour exposure to different concentrations of GlcN was performed in 
sulfate free RPMI 1640 medium with 2% FCS. After metabolic labelling in 0.1 mCi 
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35S-sulfate / ml medium for 24 hours, medium and cell fraction was harvested and 
purified by gelfiltration.  
The amount of 35S-macromolecules recovered was related to the protein 
concentration. This was used as an assessment of the de novo 35S-macromolecule 
synthesis per cell. The secretion of 35S-macromolecules per cell did not seem to be 
affected until at 1.0 mM GlcN, where we observed a decrease of 42 ± 18 % as 
compared to the control (figure 5.3, panel A). This decline continued with increasing 
GlcN concentration, reaching 20 ± 9 % of the control at 10.0 mM. As mentioned 
earlier, the cells showed altered behaviour when exposed to concentrations above 1.0 
mM. Thus, a concentration of 1.0 mM GlcN seems to be sufficient in order to see 
changes in the secreted 35S-macromolecules. As can be seen in figure 5.3 panel B, 
there was a reduction also of intracellular macromolecules, but not to the same extent 
as in the conditioned medium. The reduction at 1.0 mM was 26 ± 23 %, reaching a 
reduction of 54 ± 20 % compared to the control at 10.0 mM.  
 
 
Figure 5.3. 35S-macromolecules in HUVEC exposed to GlcN. HUVECs were cultured for 
24 hours in 0.0, 0.1, 1.0, 2.0, 5.0 and 10.0 mM GlcN and sulfate free RPMI-medium with 2% 
FCS. Metabolic labelling was performed in 0.1mCi / ml 35S-sulfate.  Cells and medium was 
harvested and samples purified by gelfiltration. The amount of 35S-labeled macromolecules 
in conditioned medium (A) and cell lysate (B) was measured as cpm and adjusted to the 
cellular protein concentration. The results are based on doublets of parallels from three 
different individuals, and presented as % of control with error bars. 
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GlcN time-response 
A change in 35S-macromolecule expression was seen after 24 hours incubation. To 
further investigate the effect of time exposure to GlcN, parallels of HUVECs from 
three individuals were exposed to 1.0 mM GlcN for more extended time periods.  
HUVECs were seeded onto 6-wells culture plates and grown in MCDB medium until 
confluent. Exposure to 1.0 mM GlcN was performed in sulfate free RPMI 1640 
medium with 2% FCS for 0, 24, 48 and 72 hours. After metabolic labelling in 0.1 
mCi 35S-sulfate / ml medium for 24 hours, medium and cell fractions were harvested 
and purified as previously described.  
From figure 5.4, panel A, it is evident that there was a reduction of 29 ± 16 % in 
secreted 35S-macromolecules from 0 to 24 hours, compared to the control. This trend 
seemed to continue with time, reaching a reduction of 57 ± 4 % of the control at 72 
hours. In cell lysates, figure 5.3 panel B, this reduction was less obvious. The 
reduction reached 51 ± 5 % of the control after 72 hours. A 24 hours exposure 
appeared to be sufficient in order to detect effects of GlcN on the expression of 35S-
macromolecules in HUVEC. 
 
Figure 5.4. 35S-macromolecules after HUVEC exposure to 1.0 mM GlcN for 0, 24, 48 and 
72 hours. Confluent cells were cultured in sulfate free RPMI-medium with 2% FCS and 1.0 
mM GlcN for the indicated times. 0.1mCi 35S-sulfate was added per ml medium for the last 
24 hours before harvesting in Guanidine / Triton X-100. Samples from both conditioned 
medium (A) and cell-lysate (B) were purified by gelfiltration.  The amount of 35S-labelled 
PGs was measured as cpm and adjusted to the cellular protein concentration. The results 
are based on doublets of parallels from three different individuals, and presented as % of 
control with error bars. 
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Effect of GlcN on 35S-proteoglycans 
Investigation of the effect of GlcN on PG expression was performed on samples 
purified from HUVEC exposed to different GlcN concentrations and for different 
durations. As mentioned in section 4.11, PGs are seen on SDS-PAGE as broad 
smears, typically at approximately >220, 220 and 95 kDa. Thus, high molecular 
bands of this kind on a SDS-PAGE of 35S-macromolecules are thought to represent 
PGs. 
GlcN dose-response 
The effect of different doses of GlcN on the de novo PG synthesis was investigated 
by visualization of 35S-PGs on SDS-PAGE.  
Parallels from the three different HUVEC cultures previously used for protein and 
35S-macromolecule measurements, were seeded onto 6-wells culture plates and grown 
in MCDB medium until confluent. The cells were exposed to 0, 0.1, 1.0, 2.0, 5.0 and 
10.0 mM GlcN and metabolically labelled with 35S-sulfate. Purified samples of equal 
protein contents and a minimum of 10 000 cpm were subjected to SDS-PAGE, as 
shown in figure 5.5. Radioactive molecules of different sizes were visible as dark 
areas at different locations in each lane, relative to the migration in the gel. The size 
was determined by comparison to molecular weight markers.   
PGs were separated on the gel into three distinct bands of >220, ~220 and ~ 95 kDa, 
as shown in figure 5.5, and the intensity of the bands correspond to the amount of 
radioactive material present. The SDS-PAGE indicated a decrease in the secretory 
PGs relative to the increasing GlcN concentration, starting at 1,0 mM GlcN (figure 
5.5, panel A). The intensity of the bands was measured by the program Scion Image 
(Table 5.1). Additionally, no new bands appeared, nor did any bands disappear. This 
suggested that there was no change in the individual PG expressions, although this 
could not be concluded, as each band theoretically could be comprised of several 
PGs. From figure 5.5, panel B it is evident that the cell fractions contained much less 
radiolabelled PGs than the medium fractions. As illustrated by Table 5.1, the total 
intensity at 1.0 mM was reduced with 28 ± 7 % relative to control. In cell-lysate, the 
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total PG amount was lower, and the decrease in intensity with increasing GlcN 
concentration was less obvious.  
 
Figure 5.5. SDS-PAGE of 35S-PGs in HUVEC exposed to 0, 0.1, 1.0, 2.0, 5.0 and 10.0 mM 
GlcN for 24 hours. After grown to confluency, the exposure was performed in sulfate free 
RPMI 1640 medium with 2% FCS and metabolic labelling with 0.1 mCi 35S-sulfate/ ml 
medium. Conditioned medium (panel A) and cell lysate (panel B) was harvested, purified by 
gelfiltration, and sample volumes of equal protein contents and a minimum of 10 000 cpm 
were separated according to size on SDS-PAGE (4-20%). Radio-labelled PGs were detected 
by film exposure. This represents the results obtained from one of three individual 
experiments, in which each concentration is performed in parallel and accordingly loaded to 
two separate lanes (except for 0 and 10.0 mM in cell lysate, due to technical problems). The 
migration positions of molecular weight markers (in kDa) are shown on the left side of the 
panel.  
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Table 5.1. Intensity of the 35S-PG-bands of the SDS-PAGE from all three experiments, 
detected with the program Scion Image. The mean intensity of each band (>250, 220 and 95 
kDa) and the mean total intensity of each lane are shown for medium (A.) and cellysate (B.) 
for each GlcN  concentration. The data are presented as % of control with standard errors. 
  Band size (kDa)  [GlcN] (mM) 
    0 0.1 1.0 2.0 5.0 10.0 
A. Medium >250 100 98 65 49 25 21 
  220 100 112 75 69 29 23 
  95 100 105 75 63 27 22 
   Total 100 104 ± 1 72 ± 7 63 ± 2 27 ± 1 22 ± 2 
B. Cell >250 100 91 80 89 59 59 
  220 100 91 83 108 63 88 
  Total 100 91 ± 3 81 ± 10 99 ± 3 61 ± 1 73 ± 2 
 
GlcN time-response 
The effects of GlcN on 35S-PGs were further investigated on parallels of HUVECs 
from three individuals exposed to 1.0 mM GlcN for 0, 24, 48 and 72 hours, as 
previously described. This de novo synthesis of PGs is illustrated in figure 5.6 by 
SDS-PAGEs of 35S-sulfate labelled macromolecules from cell lysate and conditioned 
medium.  
In line with previous observations, figure 5.6 illustrate the separation of PGs into 
three distinct bands of approximately 100, 220 and >220 kDa. The intensity of the 
bands varied with the amount of radiolabelled PGs present, and the total intensity of 
the medium samples dominated the cell lysate by far. In cell lysates, there was a total 
domination of PGs comprising the uppermost band. In both medium and cell 
fractions, there was a decreasing intensity of the bands with increasing incubation 
time. This suggested an increasing effect of GlcN with exposure time, supported by 
the data previously presented in figure 5.4. Measured as SDS-PAGE band intensity, 
the total amount of secreted 35S-PGs was reduced by 33 ± 16 % after 24 hours, as can 
be seen from table 5.2. The corresponding reduction in cell-lysate was 34 ± 11 %. 
These data were supported by the previous findings that 24 hours incubation with 1.0 
mM GlcN reduces the secretory 35S-PGs. A more modest reduction was seen in cell-
lysate with increasing time periods. The secretory PGs were of a much greater 
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abundance than the intracellular, and were increasingly affected by GlcN with 
increasing exposure time.  
 
Figure 5.6. Effect of 0, 24, 48 and 72 hours GlcN exposure on 35S-PGs in HUVEC. SDS-
PAGE of 35S-sulfate labelled macromolecules in cell lysate and conditioned medium of 
HUVECs exposed to 1.0 mM GlcN for the indicated times. After grown to confluency, the 
exposure was performed in sulfate free RPMI 1640 medium with 2% FCS and metabolic 
labelling by 0.1 mCi 35S-sulfate/ ml medium. Cells and medium was harvested, purified by 
gelfiltration, and sample volumes of equal protein contents and a minimum of 10 000 cpm 
were separated according to size on SDS-PAGE. Radiolabelled PGs were detected by film 
exposure. This is one representative of three individual experiments.  The migration 
positions of molecular weight markers (in kDa) are shown on the left side of the panel. 
Table 5.2. Intensity of the PG-bands at SDS-PAGE shown in figure 5.6, detected with the 
program Scion Image. The intensity of each band (>220, 220 and 95 kDa) and the total 
intensity of the lanes are shown for medium and cell-lysate for 0, 24, 48 and 72 hours, 
respectively. The data are presented as % of control with standard deviations. 
  Medium Cell 
Band size (kDa) 0 h 24 h 48 h 72 h 0 h 24 h 48 h 72 h 
450 100 48 48 57 100 79 74 71 
220 100 77 61 57 100 59 45 75 
95 100 76 66 49 100 62 53 104 
 Total 100 67 ± 16 58 ± 9 54 ± 4 100 66 ± 11 57 ± 15 83 ± 18 
 
Collected effects of GlcN on HUVEC 
GlcN in concentrations up to 10.0 mM did not affect the protein concentration of 
HUVEC. Concentrations above 1.0 mM were however observed to alter cell 
qualities, and 1.0 mM GlcN was therefore chosen for further experiments. Increasing 
exposure time did not seem to alter the effect of 1.0 mM GlcN on protein 
concentrations. Exposure to 1.0 mM GlcN reduced the expression of both 35S-
macromolecules and 35S-PGs. A sufficient magnitude of effect was seen after 24 
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hours. In conditioned medium, the reduction of 35S-macromolecules was 42 ± 18 %, 
and the reduction of 35S-PGs was 28 ± 7 %. In summary; HUVEC exposure to 1.0 
mM GlcN did not affect cell proliferation or viability, but did affect the expression of 
35S-macromolecules and 35S-PGs. 24 hours was sufficient time to observe this effect.  
5.1.2 Effects of high glucose and GlcN on HUVEC 
The effects of glucose and GlcN on ECs were compared by exposing HUVEC to 25.0 
mM glucose or 1.0 mM GlcN for 24 hours. Growth was monitored by cell protein 
measurements, as well as monitoring the biosynthesis of 35S-macromolecules, 35S-
PGs and individual PGs. 
Effect of Glucose and GlcN on HUVEC proliferation 
We wanted to compare the effects of glucose and GlcN on HUVEC proliferation. 
This was done by exposing HUVECs to GlcN or high levels of glucose, and 
monitoring the protein concentration as compared to concentrations from HUVECs 
grown in low levels of glucose.  
Seven confluent HUVEC cultures were exposed to low glucose (5.0 mM), high 
glucose (25.0 mM) or GlcN (1.0 mM) in RPMI 1640 sulfate free medium with 2% 
FCS for 24 hours before harvesting and purification. 
No obvious differences in protein concentration were observed when comparing the 
effect of low glucose to high glucose or to GlcN, as shown in figure 5.7. In other 
words; neither high glucose nor GlcN affected cell viability or proliferation, and there 
were no differences between glucose and GlcN in their effect on proliferation. 
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Figure 5.7. Protein concentration in HUVEC after 24 hours in low glucose (5.0 mM), 
high glucose (25.0 mM) or GlcN (1.0 mM). Confluent HUVEC cells were cultured in 
sulfate free medium with 2% FCS and low glucose (LG), high glucose (HG) or GlcN for 24 
hours, prior to harvesting, gel-chromatography purification and protein measurements. The 
data are based on doublets of parallels from seven individuals and presented as % of 
control, with error bars.  
Effect of Glucose and GlcN on 35S-macromolecules 
The effect of high glucose and GlcN on 35S-macromolecules was investigated, both in 
relation to low glucose, and to each other.  
HUVEC were grown to confluency and exposed to low glucose, high glucose or 
GlcN, in RPMI 1640 sulfate free medium with 2% FCS, and radiolabelled with 35S-
sulfate 24 hours prior to harvesting, G50 Fine purification, and finally protein and 
scintillation measurements.  
From figure 5.8, panel A, it is evident that GlcN reduced the secretion of 35S-
macromolecules with 41 ± 13 %. Intracellular macromolecules were reduced by 31 ± 
7 % (figure 5.8, panel B). High levels of glucose on the other hand, decreased the 
secretion (13 % ± 7 %) and increased intracellular levels (+ 27 % ± 16 %). 
 
 86 
 
Figure 5.8: 35S-macromolecules from HUVEC grown in low glucose (5.0 mM), high 
glucose (25.0 mM) or GlcN (1.0 mM) for 24 hours. Confluent HUVEC cells were cultured 
in sulfate free medium with 2% FCS and low glucose (LG), high glucose (HG) or GlcN, as 
well as 0.1 - 0.2 mCi 35S-sulfate / ml medium. Cells were lysed and conditioned medium 
harvested, before gel-chromatography purification and cpm and protein measurements. The 
de novo PG synthesis is illustrated as amount of 35S-macromolecules measured as cpm and 
adjusted to the protein concentration. Data from conditioned medium are found in panel A 
and from cell lysate in panel B. The data are based on doublets of parallels from five 
individuals and presented as % of control, with error bars.  
Effect of Glucose and GlcN on 35S-proteoglycans 
We wanted to investigate the effects of glucose and GlcN on the PG synthesis in 
HUVEC. The de novo synthesis of PGs can be assessed trough separation and 
visualization of radiolabelled macromolecules after SDS-PAGE. 
Cell cultures grown to confluence on 6-well plates were exposed to low glucose (5.0 
mM), high glucose (25.0 mM) or GlcN (1.0 mM) and radiolabelled with 35S-sulfate 
for 24 hours prior to harvesting and G50 fine purification, and finally separation and 
visualization of PGs on SDS-PAGE (4-20 %) as previously described. 
Separation of the 35S-PGs gave rise to three distinct bands on the SDS-PAGE, and the 
intensity of the bands indicates their relative amounts. From figure 5.9 panel A it is 
observed that the 35S-PG bands in the medium from cells treated with high glucose 
were overall equally intense, and the bands from GlcN treatment less intense, as 
compared to low glucose. From Table 5.3 it is evident that there were a  minimal 
increase of 2 ± 1 % from low  to high glucose, and a more markedly reduction of 55 
± 7 % from low glucose to GlcN in secreted PGs. This illustrate a markedly reduction 
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in the release of 35S-PGs upon GlcN exposure. In cell lysate (figure 5.9, panel B), the 
total intensity of the bands was lower. The total cellular reduction in GlcN relative to 
low glucose was 19 ± 10 %, and in high glucose relative to low glucose the reduction 
was 12 ± 1 % (Table 5.3). 
 
Figure 5.9. 35S-PGs in HUVEC exposed to LG, HG or GlcN for 24 hours. SDS-PAGE (4-
20 %) visualisation of 35S-sulfate labelled macromolecules from conditioned medium (A) 
and cell lysate (B) of HUVEC exposed to low glucose (LG, 50mM), high glucose (HG, 25.0 
mM) and GlcN (1.0 mM) for 24 hours. Confluent cells were labelled in 0.1 mCi / ml and 
samples were purified by gelfiltration after harvesting. Samples of equal volumes and 
protein content was loaded on the gel and separated before visualization by film exposure. 
This represents the results obtained from three experiments, in which each concentration is 
performed in parallel and accordingly loaded to two separate lanes. The migration positions 
of molecular weight markers (in kDa) are shown on the left side of the panel.  
Table 5.3. Intensity of the PG-bands in the SDS-PAGE shown in figure 9, detected with the 
program Scion Image. The intensity of each band (>220, 220 and 95 kDa) and the total 
intensity of each lane is shown for cell-lysate (A.) and medium (B.) for each concentration of 
GlcN. The data are presented as % of control (LG) with standard deviations. 
  Medium Cell 
Band size (kDa) LG HG GlcN LG HG GlcN 
>220 
10
0 101 40 100 89 74 
220 
10
0 103 53 100 87 88 
95 
10
0 103 43    
Total 
10
0 102 ± 1 45 ± 7 100 88 ±1 81 ± 10 
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Effect of Glucose and GlcN on PG composition in HUVEC 
SDS-PAGE separation of 35S-macromolecules gave rise to broad “PG-bands” at 
>220, 220 and 95 kDa. We wanted to investigate whether these were composed of 
HS or CS PGs. 
Three HUVEC cultures were grown to confluence and exposed to low glucose, high 
glucose or GlcN and radio-labelled with 0.2 mCi 35S-sulfate/ml medium 24 hours 
prior to harvesting and purification both by gelfiltration and ion-exchange 
chromatography. Each sample of conditioned medium was divided in four, of which 
were either left untreated or treated with cABC, HNO2 or both, and subjected to SDS-
PAGE.  
Treatment of PGs with cABC will depolymerise CS- and DS-PGs into disaccharides, 
leaving only the core protein. HS is resistant to this enzyme, and HSPGs will remain 
unaffected.  HNO2 treatment on the other hand will depolymerise HS and heparin 
without affecting CS/DS. Radio-labelled HSPGs will thus not be visible at the SDS-
PAGE of the HNO2 treated samples.  
As illustrated in figure 5.10, both in the low glucose, high glucose and GlcN samples, 
we observed that the uppermost bands at >220 kDa in the untreated samples, nearly 
disappeared after HNO2 treatment. This showed that the PGs of this band were 
predominately of the HSPG type. A band of this size corresponds to the size of 
perlecan, which can be both of the HS and of the CS type. These data thus suggested 
that perlecan in HUVEC might be a HSPG.  
In the cABC-digested samples the bands at ~ 220 and 95 kDa were markedly 
reduced, suggesting that the PGs in these bands were predominately of the CS/DS 
type. This was in agreement with the assumption that these bands consist, amongst 
others, of the HS/CS PGs serglycin and syndecan-1 at ~ 220 kDa, as well as the 
CS/DS PGs decorin and biglycan at ~ 95 kDa.  
In the double digested samples all three bands were reduced, supporting these 
observations. 
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The PG composition of the low glucose, high glucose and GlcN treated cells were 
apparently identical, as the same effects were seen after cABC and HNO2 in all 
treatments (figure 5.10, panel A, B, C). Therefore hyperglycemia did not seem to 
influence on the CS / HS ratio of PGs. The previous results illustrated in figure 5.9 
and table 5.3, show that the change in intensity of the >220 kDa band of medium was 
negligible after high glucose treatment (increase of 1 %). After GlcN exposure, 
however, a reduction of 60 % was observed. Corresponding numbers for cellysate 
were 11 % decrease in high glucose and 26 % decrease in GlcN. The intensity of the 
95 kDa band in cell lysate was to wage for identification, but in medium we observed 
a trend towards an increase (3 %) in high glucose and a decrease of 57 % in GlcN. 
 
Figure 5.10. Secreted 35S-PGs in HUVEC exposed to low glucose, high glucose or GlcN 
for 24 hours. SDS-PAGE (4-20 %) visualisation of 35S-sulfate labelled macromolecules 
from conditioned medium of HUVEC exposed to low glucose (LG, 50mM), high glucose 
(HG, 25.0 mM) and GlcN (1.0 mM) for 24 hours, in panel (A), (B) and (C) respectively. 
Confluent cells were labelled in 0.2 mCi / ml and samples were purified by gelfiltration and 
ion-exchange chromatography after harvesting, after which each sample was divided in four 
and treated with HNO2, cABC, both or none. Samples of equal volumes and protein content 
was loaded on the gel and separated before visualization by film exposure. Indication if the 
treatments are given by U: Untreated, C: cABC, H: HNO2, B: Both cABC and HNO2. The 
upper arrow indicate a molecular size of ~ 220 kDa, the lower ~ 95 kDa. This represents the 
result of three experiments.  
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Effect of Glucose and GlcN on perlecan and decorin 
HNO2 exposure and cABC digestion suggest that the >220 kDa PG in HUVEC is 
perlecan, and that the 95 kDa band contained decorin. This was investigated further, 
by Western blotting identification of the individual PGs.   
HUVEC were grown to confluence, before exposed for 24 hours in MCDB medium 
with 2% FCS and either low glucose (5.0 mM), high glucose (25.0 mM) or GlcN (1.0 
mM). Conditioned medium was recovered before cell lysis and harvesting in RIPA-
buffer. The PGs were separated from other macromolecules by DEAE ion-exchange 
chromatography, and the samples were desalted and concentrated. Each sample was 
divided in three, in which two were subjected to cABC or HNO2 digestion. Samples 
of equal protein contents were separated on SDS-PAGE (4-20 %) and the proteins 
were electroblotted on to a PVDF membrane. The blots were analyzed with 
antibodies against perlecan and decorin. The experiment was repeated three times 
with HUVEC from three different individuals. One representative blot is shown for 
perlecan in figure 5.11 and for decorin in figure 5.12.  
The fully glycosylated perlecan was identified at >220 kDa by Western blotting in 
the untreated and cABC digested samples. In HNO2 treated samples, the core was 
shown to have a molecular weight above 250 kDa. These results support the finding 
that perlecan in HUVEC is a HSPG, and that perlecan is the PG of the >220 kDa 
band on SDS-PAGE of 35S-macromolecules. Due to uneven transfer of the large PGs 
from the gel to the PVDF membrane, the Western blots were not suited for 
quantitative analyses. However, the previous experiments showed that on SDS-
PAGE the >220 kDa band was reduced with 60 % in GlcN, and unchanged in high 
glucose, related to low glucose (see Table 5.3). 
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Figure 5.11. Perlecan expression in conditioned medium of HUVEC exposed 24 hours to 
low glucose, high glucose and GlcN. HUVEC was exposed to low glucose (5.0 mM, LG), 
high glucose (25.0 mM, HG) or GlcN (1.0 mM). Conditioned medium was collected and 
purified by ion-exchange chromatography. The samples were either untreated (U) or treated 
with cABC (C) or HNO2 (H), before amounts of equal protein contents was loaded on the gel 
(4-20 % SDS-PAGE gel) and PGs separated according to size. Perlecan was identified by 
Western blotting. The results present one representative of three experiments. The migration 
positions of molecular weight markers (in kDa) are shown on the left side of the panel.  
 
Figure 5.12. Decorin expression in conditioned medium of HUVEC exposed 24 hours to 
low glucose, high glucose and GlcN. HUVEC were exposed to low glucose (5.0 mM, LG), 
high glucose (25.0 mM, HG) or GlcN (1.0 mM). Conditioned medium was collected and 
purified by ion-exchange chromatography. The samples were either untreated (U) or treated 
with cABC (C) or HNO2 (H), before amounts of equal protein contents was loaded on the 
SDS-PAGE (4-20%) and PGs separated according to size. Decorin was identified by 
Western blotting. The results presented are representatives from three experiments. The 
migration positions of molecular weight markers (in kDa) are shown on the left side of the 
panel.  
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In figure 5.12, decorin core protein was identified as strong bands at approximately 
40 kDa in the cABC treated samples. The intact decorin was seen as somewhat 
fainter bands around 95 kDa in the untreated samples and HNO2 treated samples. 
These data illustrated the fact that decorin was present and detectable in HUVEC as a 
CS/DS PG. This was supported by the results from the previous SDS-PAGE of 35S-
PGs (figure 5.9), showing that the band at ~ 95 kDa was of the CS/DS type. This 
band was decreased 57 % by GlcN and increased 3 % by high glucose, as illustrated 
by Table 5.3.  
The PGs perlecan and decorin were detected by Western blotting of conditioned 
medium from HUVEC, and qualitative analyses confirmed perlecan as a HSPG and 
decorin as a CS/DS PG. They were both found in HUVEC during normoglycemic 
and hyperglycemic conditions, and both PGs were found to be secretory products 
under in vitro conditions. 
Collected effects of Glucose and GlcN on HUVEC 
Glucose and GlcN did not seem to affect HUVEC viability and proliferation. A 
reduction in both 35S- macromolecules and PGs was observed in conditioned medium 
of GlcN exposed cells, by 41 ± 13 % and 55 ± 7 % respectively. The observed effects 
of high concentrations of glucose however, were more conflicting. The overall 
composition of PGs did not appear to be affected, neither with respect to PG size or 
the CS/DS composition. Perlecan and decorin were expressed in HUVEC exposed to 
both a normal and hyperglycaemic environment. Perlecan was shown to comprise the 
>220 kDa 35S-PG SDS-PAGE band, and decorin was found in the ~ 95 kDa band. 
Perlecan in HUVEC has HS-chains and decorin has CS/DS chains, and the CS/HS 
composition did not seem to be affected by GlcN or high levels of glucose. Results 
from the previous experiment show that the relative intensities of the >220 (perlecan) 
and 95 kDa band (decorin) on SDS-PAGE were reduced by 60 % and 57 %, 
respectively, upon GlcN exposure. High glucose did not show conclusive effects on 
either PG  
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5.2 Effect of inflammatory conditions on proteoglycan 
synthesis 
Hyperglycemia induces the atherosclerotic chronic inflammation of the vessels seen 
in DM. To further study PGs as a link between DM and vascular damage, ECs were 
exposed both to inflammatory conditions. 
5.2.1 Effect of inflammatory conditions on HUVEC 
Diabetic hyperglycemic conditions may lead to low-grade inflammatory conditions in 
the circulatory system. To study the possible implications of inflammation on PGs, 
ECs were exposed to the pro-inflammatory mediators IL-1α and TNF-α, and the 
effect on both cell proliferation and on radiolabelled macromolecules / PGs was 
studied. 
Effect of inflammatory conditions on HUVEC proliferation 
We wanted to investigate the effect on HUVEC proliferation upon exposure to IL-1α 
and TNF-α. Confluent HUVEC were cultured in RPMI sulfate free medium with 2% 
FCS and 5.0 mM glucose, and exposed for 24 hours to IL-1α (2.0 ng/ml) or TNF-α 
(7.0 ng/ml) (60), compared to cells grown only in the low glucose medium. The cells 
were harvested in Guanidine / Triton X-100, before gel filtration purification and 
protein determination.  
These data indicate a slight increase in protein concentration after IL-1α exposure, as 
seen in figure 5.13.  However, there was no change in protein concentration after 
exposure to TNF-α.  
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Figure 5.13. Protein concentration in HUVEC after 24 hours in low glucose (5.0 mM), 
IL-1α (2.0 ng/ml) or TNF-α (7.0 ng/mL). Confluent HUVEC cells were cultured in sulfate 
free medium with 2% FCS and low glucose, IL-1α or TNF-α for 24 hours, prior to 
harvesting, gel-chromatography purification and protein measurements. The data are based 
on doublets of parallels from three individuals and presented as % of control, with error 
bars.  
Effect of inflammatory conditions on 35S macromolecules 
The effect of the inflammatory mediators on macromolecules was further investigated 
after 35S-labelling.  
HUVEC was cultured to confluence in MCDB-medium, after which they were grown 
in sulfate free RPMI 1640 medium with 2% FCS and low glucose (5 mM), IL-1α (2.0 
ng/ml) or TNF-α (7.0 ng/ml) for 24 hours. The de novo synthesis of 35S-
macromolecules during these 24 hours was assesses by measuring the amount of 35S 
macromolecules after gelfiltration.  
From figure 5.14, panel A, it is evident that there was a profound increase in secreted 
35S- macromolecules after IL-1α exposure of 20 % ± 10 %. A trend towards a 
reduction was seen after TNF-α exposure; which decreased 14 ± 13 %. Intracellular 
macromolecules were reduced by 11 ± 8 % in IL-1α and 36 ± 21 % in TNF-α 
exposed samples, as illustrated in figure 5.14, panel B.  
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Figure 5.14. 35S-macromolecules from HUVEC grown in low glucose (5.0 mM), IL-1α 
(2.0 ng/ml) or TNF - α (7.0 ng/mL) for 24 hours. Confluent HUVECs were cultured in 
sulfate free medium with 2% FCS and low glucose (LG), IL-1α or TNF-α for 24 hours, as 
well as 0.2 mCi 35S-sulfate / ml medium. Cells were lysed and conditioned medium 
harvested, before gel-chromatography purification and cpm and protein measurements. The 
de novo PG synthesis in conditioned medium (A) and cell-lysate (B) is illustrated as amount 
of 35S-macromolecules measured as cpm and adjusted to the protein concentration. The data 
are based on doublets of parallels from two individuals and presented as % of control, with 
error bars.  
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Effect of inflammatory conditions on 35S-proteoglycans 
The effect of inflammation on the de novo synthesis of total amount of PGs was 
studied by radiolabelling and visualisation on SDS-PAGE. 
HUVEC from two individuals were cultured and exposed 24 hours to low glucose 
(5.0 mM), IL-1α (2.0 ng / mL) or TNF-α (7.0 ng / ml) and radiolabelling, and 
analysed by SDS-PAGE in the previously described manner. Due to limited amount 
of material, only conditioned medium was analysed, not cell-lysates. From figure 
5.15 and table 5.4 it is evident that there was a small increase in 35S-PGs in the 
medium after IL-1α exposure, whereas no effect was observed after TNF-α treatment.  
 
Figure 5.15 . SDS-PAGE of secreted 35S- labelled PGs in HUVEC.  35S- labelled 
macromolecules was recovered from the medium of HUVEC treated for 24 hours with low 
glucose (LG), IL-1α or TNF-α and purified by gelfiltration. Samples of equal volume and 
protein contents were subjected to SDS-PAGE (4-20 %). The migration of high molecular 
weight markers is shown on the left side (in kDa). This is one representative of two 
experiments. 
Table 5.4. Intensity of the PG-bands from the SDS-PAGE shown in figure 5.16, detected 
with the program Scion Image. The intensity of each band (>220, 220 and 95 kDa) and the 
total intensity of the lanes are shown for low glucose (LG), IL-1α and TNF-α. The data are 
presented as % of control. 
Band size (kDa) LG IL-1α TNF-α 
450 100 103 94 
220 100 104 105 
95 100 113 111 
 Total 100 107 101 
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Effect of inflammatory conditions on PG composition in HUVEC 
The SDS-PAGE separation of 35S-macromolecules shown in Figure 5.16 gave rise to 
broad “PG-bands” at >220, 220 and 95 kDa. We wanted to investigate whether 
inflammatory conditions affected the synthesis of HSPGs or of CSPGs. 
HUVEC from two individuals were cultured and exposed for 24 hours to low glucose 
(5.0 mM), IL-1α (2.0 ng / ml) or TNF-α (7.0 ng / ml) as previously described. 
Samples obtained were treated with c-ABC, HNO2 or both, and subjected to SDS-
PAGE.   
Both in the low glucose, IL-1α and TNF-α treated samples, we observed that the 
uppermost bands at >220 kDa nearly disappeared when HNO2 treated, indicating that 
the PGs in this band are predominately of the HSPG type (figure 5.16). This size 
corresponds to the size of the PG perlecan, which can be both of the HS and of the 
CS type. These data support the finding from the high glucose and GlcN treated cells; 
that perlecan in HUVEC is a HSPG. 
After cABC-digestion, the bands at ~ 220 and 95 kDa were markedly reduced, 
suggesting that the PGs comprising these bands are predominately of the CS/Ds type. 
This is in agreement with our previous assumption that these bands consist, amongst 
others, of the HS/CS PGs serglycin and syndecan-1 at ~ 220 kDa, as well as the 
CS/DS PGs decorin and Biglycan at ~ 95 kDa.  
No conclusions could be made about the changes in the >220 kDa “perlecan” band 
after IL-1α or TNF-α treatment, shown in previous experiments (Table 5.4) to be 
increased 3 % by IL-1α and reduced 6 % by TNF-α. A more distinct reduction was 
seen in the “decorin band” which was increased 13 % by IL-1α and 11 % by TNF-α. 
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Figure 5.16. Secreted 35S-PGs in HUVEC exposed to low glucose, IL-1α or TNF- α for 24 
hours. SDS-PAGE (4-20 %) visualisation of 35S-sulfate labelled macromolecules from 
conditioned medium of HUVEC exposed to low glucose (LG, 5.0 mM), panel A, IL-1α (2.0 
ng/ml), panel B and TNF-α (7.0 ng/ml), panel C. Confluent cells were labelled in 0.2 mCi / 
ml and samples were purified by gelfiltration and ion-exchange chromatography after 
harvesting, after which each sample was divided in four and treated with HNO2, cABC-
enzyme, both or none. Samples of equal volumes and protein content was loaded on the gel 
and separated before visualization by film exposure. Indication if the treatments are given 
by U: Untreated, C: cABC, H: HNO2, B: Both cABC and HNO2. The upper arrow indicate a 
molecular size of ~ 220 kDa, the lower ~ 95 kDa. This represents results from two 
experiments. 
Effect of inflammatory conditions on perlecan and decorin 
HNO2 exposure and cABC digestion to HUVEC in normal and inflammatory 
conditions suggest that the >220 kDa PG in HUVEC is perlecan, and that the 95 kDa 
band contains decorin. This was investigated further by Western blotting.   
Confluent HUVEC were exposed to IL-1α or TNF-α for 24 hours. Cells were lysed in 
RIPA-buffer, and conditioned medium and cell lysates collected and purified as 
previously described. Samples of equal protein contents were separated on SDS-
PAGE (4-20 %) and analyzed for perlecan (figure 5.17) and decorin (figure 5.18) 
using Western blotting.  
Perlecan was identified by Western blotting both in medium (figure 5.17, panel A), 
and only faintly in cell-lysate (figure 5.17, panel B). The intact perlecan PG was 
observed mainly in untreated and cABC digested samples, at >220 kDa. The core 
protein was seen only in the HNO2 treated samples as a band at approximately 200 
kDa. These findings implicate that perlecan is predominately a HSPG, both during 
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normal and inflammatory conditions. These findings support the results obtained 
from the SDS-PAGE of figure 5.16 that the >220 kDa band is perlecan. As 
demonstrated in table 5.4, no changes were detected in the intensity of this band on 
SDS-PAGE after IL-1α or TNF treatment. 
In contrary to perlecan, decorin was only identified in the medium fractions (figure 
5.18). The core protein was observed as strong bands at approximately 40 kDa in the 
cABC treated samples, and the intact PG was seen as bands around 95 kDa in the 
untreated and HNO2 treated samples. These data illustrates the fact that decorin is 
present in HUVEC and detectable on SDS-PAGE and after Western at 95 kDa, and 
supports the fact that decorin is a CS/DS PG. This seemed to be the case both in 
normal and inflammatory conditions. This supports the data from the SDS-PAGE 
(figure 5.16) that the 95 kDa band was comprised of CSPGs. This band was increased 
13 % upon IL-1α exposure and 11 % after TNF-α stimulation as detected from SDS-
PAGE (figure 5.15, table 5.4). 
 
Figure 5.17. Perlecan expression in HUVEC exposed 24 hours to low glucose, IL-1α and 
TNF-α. HUVEC was exposed to low glucose (5.0 mM, LG), IL-1α (2.0 ng/ml) and TNF-α 
(7.0 ng/ml). Both conditioned medium (panel A) and cell-lysate (panel B) was collected and 
purified by ion-exchange chromatography. The samples were either untreated or treated 
with cABC or HNO2, before samples of equal protein contents was loaded on the SDS-PAGE 
(4-20 %) and PGs separated according to size. Perlecan level was determined by Western 
blotting. These data are representative of three experiments. The arrows indicate a 
molecular size of 220 kDa.  
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Figure 5.18. Decorin expression in HUVEC exposed 24 hours to low glucose, IL-1α and 
TNF-α. HUVEC was exposed to low glucose (5.0 mM, LG), IL-1α (2.0 ng/ml) and TNF-α 
(7.0 ng/ml). Conditioned medium was collected and purified by ion-exchange 
chromatography. The samples were either untreated or treated with cABC or HNO2, before 
samples of equal protein contents was loaded on the SDS-PAGE gel (4-20 %), and PGs 
separated according to size. decorin level was determined by Western blotting. The blot is 
representative of three different experiments. The migration positions of molecular weight 
markers (in kDa) are shown on the left side of the panel.  
Collected effects of IL-1α and TNF-α on HUVEC 
IL-1α, but not TNF-α, have possibly stimulating effects on HUVEC proliferation, 
measured as increase in protein contents. There were indications of a stimulating 
effect of IL-1α on 35S-macromolecule and 35S-PGs secretion in HUVEC, whereas the 
effect of TNF-α was more questionable. Cellular levels seemed to be less affected. 
Perlecan and decorin were identified as the >220 and 95 kDa PGs in HUVEC. 
Perlecan was identified as a HSPG in HUVEC, and decorin as a CS/DS PG. This was 
true in HUVEC both during inflammatory and normal conditions. 
5.3 Assembled effects of hyperglycemic and 
inflammatory conditions on HUVEC 
Exposure to 1.0 mM GlcN did not affect cell proliferation or viability of HUVEC. It 
did however affect the level of secreted 35S-macromolecules in the range of 29 ± 16 
% to 42 ± 18 % and 35S-PGs in the range of 28 ± 7 % to 55 ± 7 %. The corresponding 
reductions observed in cell lysate were in the range of a 5 ± 23 % to 31 ± 19 % 
reduction in 35S-macromolecules, and in the area of a 19 ± 10 % to 34 ± 11 % 
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reduction in 35S-PGs. 24 hours exposure under in vitro conditions was sufficient to 
see this effect. 
Neither Glucose nor GlcN seemed to affect HUVEC viability and proliferation. 
However, as noted, a reduction in both 35S- macromolecules and PGs was observed in 
the conditioned medium of GlcN exposed cells. The effects of high glucose, however, 
were more uncertain. IL-1α, but not TNF-α, had a possibly stimulating effect on 
HUVEC proliferation, measured as protein contents. There were also indications of a 
stimulating effect of IL-1α on secreted 35S-macromolecules (20 ± 10 % increase) and 
35S-PGs (7 % increase) in HUVEC, whereas the effect of TNF-α was more 
questionable. Cellular levels seemed to be less affected. 
Perlecan in HUVEC was found to be a HSPG, and decorin a CS/DS PG. The >220 
kDa band on the SDS-PAGE of 35S-macromolecules was identified as the PG 
perlecan, and decorin was identified in the 95 kDa band. Thus, after metabolic 
labelling with 35S-sulfate and purification of the samples, the radiolabelled 
macromolecules obtained consisted mainly of PGs. The amount of 35S-PGs detected 
on film can be used as an assessment of the de novo PG synthesis. 
Exposure of GlcN resulted in a 60 % reduction in perlecan and a 57 % reduction in 
decorin, whereas no such changes were observed in high glucose. IL-1α The level of 
perlecan was shown to be reduced by 60 % upon GlcN exposure. The effects of 
inflammation were more variable. Decorin was reduced by 57 % in GlcN, and 
increased by 13 and 11 % by IL-1α and TNF-α. The effects of high glucose on 
perlecan and decorin were inconclusive. 
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6. Discussion 
Changes in PG expression are suspected to be involved in the development of 
diabetic complications (58;59;68). DM is associated both with hyperglycemia and 
atherosclerotic chronic inflammation of the vessels. Hyperglycemic conditions can be 
mimicked in vitro both by exposing cultured cells to high glucose, as well as high 
concentrations of glucose metabolites such as GlcN, and diabetic inflammatory 
conditions can be mimicked by using pro-inflammatory cytokines such as TNF-α and 
IL-1α (18).  
With this is mind; In order to explore the role of PGs in DM, we studied the effects of 
hyperglycemic and inflammatory conditions on PG synthesis in HUVEC. We studied 
the effects of high glucose, GlcN, IL-1α and TNF-α on cell proliferation, total PG 
production and changes in the expression of the important PGs perlecan and decorin, 
in particular.  
The most commonly used sources of human endothelial cells to study specific 
characteristics and a range of patho-physiological processes, are Human Umbilical 
Vein Endothelial Cells, HUVEC, isolated from the vein of the umbilical cord (69). 
HUVEC were isolated from different donors of different backgrounds, and therefore 
carry distinct qualities. The biological variation of the population will therefore be 
more visible than if working with an established cell line. This is reflected in the 
variation of the data obtained. A possible objection to the use of HUVEC however, 
could be the fact that they are derived from immune-privileged foetal tissue, and may 
not be representative for adult endothelium.  
Hyperglycemia is an independent risk factor for cardiovascular disease in diabetic 
patients, although the link is unclear. In vivo studies associate high glucose with a 
decrease in HSPGs (30;68;70;71). A decrease in HSPG in vitro, will increase 
monocyte adhesion to endothelium and accelerate atherogenesis (54;68), and a loss of 
endothelial HS has been postulated to lead to severe pathological events, in particular 
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event related to atherosclerosis. Loss of endothelial glycocalyx in vivo is also 
observed during hyperglycemia (20). Perlecan is the major extracellular HSPG, 
shown to be negatively correlated to inflammation, atherosclerosis and DM (24). 
CS/DS PGs are possibly increased, showing an increase in expression in human 
placentas of patients with gestational DM (72). Other studies do not demonstrate such 
an effect (68).  Decorin is a prominent CS/DS PG, which is observed to increase 
during atherosclerosis (30). GlcN is a glucose metabolite increased in hyperglycemia. 
Current studies show that glucose and GlcN have distinct effects on vascular HSPG 
(24). Unlike glucose, GlcN was suggested to increase matrix HSPG (perlecan) in 
endothelial cells (24). However, the opposite effect is observed in chondrocytes (73). 
Finally, others report that vascular PG synthesis is not affected at all by metabolic 
factors associated with DM such as high glucose (74). Hyperglycemia is known to 
promote inflammation (55). The effect of the pro-inflammatory cytokines IL-1α and 
TNF-α are reported to increase PG production (60). 
6.1 Effects of hyperglycemia on PG synthesis 
6.1.1 Effect of GlcN on HUVEC 
Among several mechanisms proposed to explain the link between hyperglycemia and 
vascular dysfunction is changes in the hexosamine pathway, where glucose is 
converted to GlcN. GlcN is the precursor for PG biosynthesis, as well as serving as 
substrate for O-GlcNAcylation of proteins. The effects of GlcN on HUVEC were 
investigated, both by looking at the effects on proliferation, and by investigating the 
effects on expression of 35S- macromolecules and 35S-PGs.  
Different concentrations of GlcN were administered to the cells, and the effects on 
both 35S- macromolecules and 35S-PGs were investigated. A substantial reduction in 
PG expression was seen after incubating HUVEC in 1.0 mM GlcN for 24 hours, 
without seeing any effect on cell viability.  
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A decrease in HSPGs in endothelial cells is associated with increased atherosclerosis. 
The results obtained here thus suggest that diabetic complications associated with 
hyperglycemia could, in part, be due to an increase in the glucose metabolite GlcN. 
The observed reduction in PGs upon GlcN exposure is in conflict with some other 
findings, such as the report of Duan, W. et al. (24). As GlcN is a precursor for GAG 
biosynthesis, an increase in GAGs following increased GlcN levels, is 
comprehensible. However, GlcN is also utilized for the glycosylation of proteins 
including certain transcription factors (23). Glycosylation state of the transcription 
factors affects their activity (26). Thus, it is conceivable that GlcN treatment increase 
the glycosylation of transcription factors involved in PG expression, which is a 
challenging topic for further research. 
Additionally, different endothelial cells could respond very differently to identical 
environments. Duan et al. performed experiments on Bovine aortic endothelial cells, 
exposing them to 2.5 mM GlcN for 16 hours. This represents different conditions 
than in the present study. Contradictory effects of GlcN in different cells could be the 
result of variations in GLUT expression. GlcN are transported into cells by GLUT 1, 
2 and 4. GLUT 1 and 4 has the same affinity for glucose and GlcN, but GLUT 2 has 
a 10-20 fold higher affinity for GlcN (75). Thus, the expression of glucose 
transporters by various cells could affect the uptake, cytosolic concentration and 
hence the effect of GlcN. GLUT l is expressed at high levels in all foetal tissues, and 
is also abundant in adult tissue endothelial cells (15;16). 
The concentration of GlcN used in the experiments also influence on the results; 
GlcN concentration found in the blood is normally in the range of 60-80 µM (75), 
much lower than the 1.0 mM used in the present study, and far lower than the 2.5 
mM used by Duan et al. Also, administering GlcN extracellularly might not mimic 
hyperglycaemic conditions in a satisfactory way. In hyperglycemia, high levels of 
glucose in the blood will lead to increased uptake by concentration-dependent 
glucose transporters and hence increased intracellular levels of glucose. This 
increasing intracellular level of glucose will lead to an increased conversion into 
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GlcN, and hence increased flux trough the hexosamine pathway. Thus, increased 
levels of GlcN are seen intracellularly, but not extracellularly in hyperglycemia 
(76;77), and it is not known whether extracellularly administration will give the same 
effects. 
6.1.2 Effects of high glucose and GlcN on HUVEC 
The effect of glucose and GlcN on PGs in endothelial cells was compared. Glucose is 
thought to exert some of its effects by way of the metabolite GlcN and the 
hexosamine pathway. Therefore, GlcN was administered as a way of enhancing the 
possible effects of glucose. Comparison of the effect of GlcN and glucose will give 
information about how glucose affects PG synthesis in endothelial cells; whether the 
effects of glucose are trough transformation to the metabolite GlcN and the 
hexosamine pathway, or whether other effects could be of more importance.  
In contradiction to GlcN, exposing HUVEC to high glucose is a more established 
procedure. The aim is to mimic human hyperglycaemic conditions. DM is diagnosed 
by a non fasting plasma glucose of ≥ 11.1 mM (78), and will vary throughout the day. 
25 mM glucose is a common concentration used when mimicking hyperglycemia in 
cell cultures (54;79). This concentration is higher than 11 mM, but is a concentration 
observed in human with hyperglycemia. Additionally, glucose is only added when 
changing medium, whereas human has a constant supply of glucose. Finally, in vitro 
experiments often require an exaggerated exposure in order to show the effects 
experienced in vivo in short term experiments.  
Neither glucose nor GlcN was shown to affect cell proliferation. The de novo 
biosynthesis and secretion was assessed by investigation of 35S-macromolecules and 
35S-PGs (figure 5.8 & 5.9). The effect of high glucose on PG expression was not as 
pronounced as the effect of GlcN. GlcN was shown to decrease PGs, but we could 
not observe such changes after high glucose treatment. These results could possibly 
support the notion that glucose and GlcN has distinct effects on PGs (24). A great 
deal of publications suggest a decrease in HSPG upon high glucose exposure of cells 
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in vitro (30;68;70;71). CSPGs however, are observed to remain unaffected (71) or to 
increase (30). Thus, the total expression of PGs could remain unaltered, even if the 
expression of individual PGs were altered. In contrast, a reduction in total secreted 
PGs upon high glucose was reported by Gharagozlian et al. (54). These experiments 
were performed on HUVEC, but under slightly different conditions than in the 
present study. 80 % confluent cells, as opposed to 100 % confluent, were exposed to 
high glucose for a length of 4 days, in contrast to 24 hours. Also, the labelling with 
35S-sulfate was performed under serum-free conditions. All this taken together could 
possibly explain the lack of ability to reproduce the results of Gharagozlian et al. 
Clearly, effects on HSPGs versus CSPGs must be investigated further.  
In order to address the question of how hyperglycemia will affect the expression of 
HS versus CS PGs, 35S-macromolecules were separated according to size on SDS-
PAGE. The GAG-chain composition of the PGs was investigated by comparing 
untreated samples to samples treated with cABC, HNO2, or both, as illustrated in 
figure 5.10. The >220 kDa band was found to be composed predominately of HSPGs, 
and the 220 and 95 kDa bands was dominated by CS/DS PGs. This pattern after SDS-
PAGE separation was identical in HUVEC exposed to low glucose, high glucose and 
GlcN, thus the CS/HS composition of each band was not altered under these 
circumstances. Additionally, these results also suggest that the observed effects of 
GlcN and high glucose on total PGs are also representative for the effect on HSPGs 
and CSPGs. It would however be interesting to investigate the effects on individual 
PGs, as both the HSPG-band and the CSPGs bands could represent more than one PG 
each, with different functions and responses to hyperglycemia. 
Thus, analysis of the individual PGs perlecan and decorin were performed. Perlecan 
is the most prominent HSPG in endothelial cells (30;44;50;80), a major 
basementmembrane PG with a multitude of important functions such as modulation 
of growth factors and angiogenic activity, effect on cell-cell and cell-matrix adhesion 
and motility. Structural changes in perlecan in endothelium is observed during 
hyperglycemia (71). Decorin is a smaller SLRP matrix PG found in endothelium 
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(45;81), which may have a pathogenic role in DM. Decorin is observed to be 
produced by capillary ECs during angiogenesis associated with a profound 
inflammation (82).  
Western blotting analyses identified perlecan as the > 220 kDa PG and decorin as the 
95 kDa PG in HUVEC (figure 5.11 and 5.12). HNO2 and cABC digestion of the 
samples identified perlecan as being a HSPG with a core protein of approximately 
350 kDa. Decorin was shown to be a CS/DS PG with a core protein of approximately 
40 kDa. This is in correspondence to earlier findings, identifying decorin as a 90 kDa 
CSPG with a core protein of 40 kDa (83). Perlecan may contain both HS and CS 
chains (42;43;84), but is previously fond to be an HSPG in endothelium (71). These 
results then suggest perlecan as the major HSPG in HUVEC.  
Hyperglycemic conditions such as high glucose or GlcN did not seem to affect the 
presence of perlecan or decorin (figure 5.11 and 5.12). Thus, there were no 
indications of a change in the composition of different PGs during hyperglycemia. 
Also, the HS / CS composition of each of the PGs present did not seem to be altered 
(figure 5.10). Perlecan was found to be a HSPG in all cases.  
Both Western blots illustrate the fact that the core protein is frequently visible as a 
more intense band than the fully glycosylated PG. This is probably due to the 
improved availability of the antibody for binding to the core protein after removal of 
GAG-chains.  Similarly, HNO2 treatment occasionally gave rise to a nearly invisible 
core protein. This result could be due to the harsh HNO2treatment at pH 1.5. PGs 
with few GAG-chains protecting the core protein, such as decorin, could suffer from 
degradation of the core protein in HNO2. To avoid this problem, in future 
experiments heparitinase will be used and not HNO2.  
The quantity of the individual PGs could not be assed by Western blotting due to 
uneven transfer from the SDS-PAGE to the PVDF-membrane. This is most likely due 
to the big size of the PGs. To obtain more quantitative data, blotting methods for PGs 
should be optimized. The success of blotting could be affected by a multitude of 
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factors, such as blotting buffer composition, time and current of electroblotting, and 
type of membrane. Alternatively, precise quantifications could rather be performed 
by for instance ELISA assays. Sufficient and even transfer of the PGs can be 
controlled by visualization of proteins in way of Coomassie blue staining of the gel 
after blotting, or by reversible staining of the membrane with Ponceau red. However, 
having identified perlecan as the >220 kDa PG and decorin as the 95 kDa PG, these 
could be quantified from the SDS-PAGE separation of the PGs. The most apparent 
changes were seen for perlecan and decorin after GlcN treatment, were the reduction 
were 60 and 57 % respectively. GlcN is thus suggested to affect the total expression 
of PGs.  
GlcN was observed to inhibit PG expression, while no such effect could be observed 
by glucose. However, if glucose exerts some of its effects via GlcN and the 
hexosamine pathway, a direct stimulus by GlcN would be expected to give a more 
obvious effect than when stimulating with glucose alone. These experiments thus do 
not exclude the fact that glucose might act on PG synthesis trough stimulation of the 
hexosamine pathway. The effects of GlcN could be masked by opposite effects of 
glucose, exerted trough other metabolic pathways. Clearly, more experiments must be 
conducted to clarify this issue. 
Effect of inflammatory conditions on PG synthesis 
Arterial PGs are considered to be important in atherogenesis due to their ability to 
trap lipid inside the vessel wall and to influence cellular migration and proliferation. 
Atherosclerotic lesions have displayed an altered PG content and distribution (59). In 
order to understand the possible implications of inflammation on PGs, ECs were 
exposed to the pro-inflammatory mediators IL-1α and TNF-α, and the effect on both 
cell proliferation and on de novo biosynthesis and secretion of PGs was studied.  
The serum levels of TNF-α  in diabetic subjects have been measured in the range 2.45 
– 3.8 pg / ml (55;55;85). In the same studies, the normal controls were in the range of 
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1.58 – 3.3 pg / ml. IL-1α serum concentrations in subjects with recently diagnosed 
DM type have shown to be in the range 59 – 1421 pg / ml, whereas normal controls 
were in the range 23 – 233 pg / ml (86). The concentrations used in these studies are 
based on the reports from Kulset et al (60), showing that 2 ng/ml IL-1α and 7 ng/ml 
TNF-α were the most potent concentrations in inducing HUVEC serglycin mRNA 
expression in vitro for 24 hours.   
The data presented in figure 5.13 indicate an increase in protein concentration after 
IL-1α exposure. However, there are no indications towards a change in protein 
content after exposure to TNF-α. The latter is in correspondence to the observations 
by Kulseth et al. where incubation in TNF-α and IL-1α did not significantly affect the 
viability of HUVEC (60).  
Our experiments, describing the effect of IL-1α and TNF-α on 35S-macromolecules, 
indicated an increase in secretion upon IL-1α exposure, but suggest a slight reduction 
upon TNF-α (figure 5.14A). Corresponding data from cell-lysate indicated a 
reduction upon both cytokines (Figure 5.14B). However, the standard errors are of 
such a great magnitude, making it difficult to conclude with certainty. Analyses of the 
changes in secreted 35S-PGs upon the same conditions did suggest an increase after 
IL-1α exposure, and a negligible increase after TNF-α exposure. However, this also 
are merely indications, as the experiments were not performed with sufficient number 
of parallels. These experiments must be repeated with more HUVEC cultures in order 
to show the trends more clearly. 
As previously mentioned and discussed later, the 35S-macromolecules can be taken to 
represent the PGs in our samples. Thus an increase in the de novo PG biosynthesis 
and secretion is observed upon IL-1α, but no effect is seen after TNF-α exposure. 
This observed increase in PGs after IL-1α exposure in HUVEC is also seen in the 
study performed by Kulseth et al.(60). Our observations of the effects of TNF-α 
however, are in conflict with the results obtained from this study, where they showed 
a 2.5 times increase of serglycin mRNA levels upon 24 hours TNF-α exposure. The 
increase with IL-1α was lower, but significant. The serglycin m-RNA level was taken 
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to represent the total PG production. However, the experiments of Kulseth et al. were 
performed under slightly different conditions than ours, which could have influenced 
on the results. As an example, the m-RNA data were obtained from HUV-EC-C 
(Human umbilical vein endothelial cell line) in contrast to the primary HUVEC used 
in our experiments. These could possibly have some different characteristics. Also, 
the experiments were performed under slightly different culturing conditions, 
regarding the composition of the culturing medium and the culture flask coating. On 
the other hand, other researchers has reported a decrease in endothelial HSPG when 
exposed to TNF-α (87), and suggest a decrease in HS might be a general 
inflammatory reaction (24).  
Atherosclerosis is considered in part to be a consequence of the chronic low-grade 
inflammation seen in DM (18). Inflammation is an important feature of plaque 
initiation and progression, and recruitment of leukocytes from the circulation to the 
site of tissue injury is essential for effective immune response. HSPGs are required 
for several stages of this entry process, binding and presenting chemokines, inducing 
adhesion of leucocytes (31). Additionally, PGs are thought to act as co-receptors for 
several signalling molecules such as growth factors and cytokines, binding to HSPGs 
on the EC surface (57). Thus, an increase in PGs upon IL-1α exposure could be a 
direct response to an inflammatory environment. In contrast to these considerations, 
evidence suggests that a disruption of the glycocalyx upon atherogenic stimuli 
increase vascular vulnerability for atherogenesis (19;33). An inflammation-induced 
shedding of the endothelial glycocalyx has been suggested to be an essential 
component in the inflammatory response of the vasculature. Thus, whether a 
reduction in HSPGs is linked to inflammation or not, is not yet determined. 
Alternatively, other metabolic alterations of HSPGs could be important during 
inflammation, such as changed GAG composition, length or sulfation.  
HSPGs are suggested as important players in the inflammatory process. The effect of 
inflammation on PGs was further investigated trough the effects on HS/CS 
composition. The HS/CS composition of the bands resulting from separation of 35S-
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macromolecules on SDS-PAGE was determined by cABC and HNO2 treatment. The 
>220 kDa band was composed of HSPGs, and the 220 and 95 kDa bands were 
CS/DS PGs. This composition was not altered when exposing HUVEC to 
inflammatory conditions. The pattern was identical after all three treatments (Figure 
5.16), which indicate that inflammation does not alter the composition of the PG 
GAGs. This cannot be concluded, however, because each band on the SDS-PAGE 
could possibly be composed of different PGs. There could be individual changes in 
PG composition, but if opposite not visible in the total band. Investigation of the 
individual PGs are needed to address this. In addition, analyses of possible changes in 
HS and CS structure should be undertaken.  
Analyses of the individual PGs perlecan and decorin were performed. Western 
blotting identified both perlecan as the > 220 kDa PG and decorin as the 95 kDa PG 
in HUVEC (Figure 5.17 & 5.18). Inflammatory conditions did not seem to affect the 
presence of perlecan or decorin, as the ratio of the PGs was not altered during IL-1α 
or TNF-α exposure. Neither was the CS/HS composition of each of the PG affected, 
as perlecan was identified as a HSPG and decorin as a CSPG in all cases. 
Collectively, these results indicate that the observed effects of inflammation on the 
total PG expression might also be representative for the effects on individual PGs. 
Inflammation was not shown to change the total composition of PGs, nor the HS/CS 
composition of each PG.     
Perlecan and decorin could not be quantified by Western blotting due to uneven 
transfer of the large PGs, as previously discussed. However, as discussed later, 35S-
macromolecules separated on SDS-PAGE visualize the PGs found in the samples. 
Perlecan was identified as the >220 kDa PG on SDS-PAGE, and decorin was 
identified as the 95 kDa CSPG. This implies that perlecan and decorin could be 
quantified by analysing the intensity of these two bands on the SDS-PAGE (figure 
5.16). The data presented suggest a possible decrease in decorin release both in IL–1α 
and TNF-α treated HUVEC, but no consistent change was observed in perlecan 
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expression.  However, the changes observed by this method, are not reproducible 
enough to allow definitive conclusions. 
The change in 35S-macromolecules and 35S-PGs observed after IL-1α exposure 
correspond to the change seen in the expression of decorin, but not in perlecan. This 
indicates a change in the expression of PGs other than perlecan. However, the >220 
kDa band representing perlecan at the SDS-PAGE is saturated and changes could 
thus be undetectable. More detailed studies including time-studies are clearly needed 
to address this question.  
 
The changes described in PG expression are based upon radiolabelling of the highly 
sulfated PGs with 35S-sulfate added to the medium and incorporated into newly 
synthesized PGs. This method is excellent, enabling us to detect and study the de 
novo synthesis of PGs, without any interference of PGs already present in the cells, 
medium, serum etc. Thus, the amount of 35S-sulfate incorporated into 
macromolecules is used as a measurement of the amount of sulfated macromolecules 
synthesized. Sulfate containing macromolecules in addition to PGs will also be 
labelled, but after purification by G-50 fine gel chromatography, PGs was shown to 
comprise the major part of the labelled macromolecules. 35S-macromolecules were 
purified by gelfiltration before separated according to size on SDS-PAGE. This gave 
rise to broad smears at >220, ~220 and ~95 kDa, recognized as bands typically 
observed when separating PGs on SDS-PAGE (52;54;63;71;83;88). These bands 
were found to be composed of HS or CS PGs, respectively. Western blotting 
demonstrated that the >220 kDa band was comprised of the HSPG perlecan, and the 
95 kDa band was found to contain CS/DS PG decorin. Thus; the 35S-macromolecules 
was demonstrated to be predominately PGs, and this method could be used further as 
a tool to describe the de novo biosynthesis and secretion of PGs, both by radioactivity 
measurements or by visualization on SDS-PAGE. This finding is also supported by 
others (54;89). 
 113
Alterations in 35S-PGs could indicate a change in number of PGs. However, the 
alterations in 35S-sulfate incorporation into PGs may indicate structural modifications 
of the PGs rather than altered numbers of PGs. Both the number of GAGs, size of 
each GAG and sulfation of the GAGs could be affected and give rise to the observed 
changes in 35S-PGs. Finally, changes in PG expression could be due to alteration in 
the degradation of both GAGs and PGs, in contrast to PG synthesis.  
Additional analyses are clearly demanded in order to make any conclusions regarding 
the causes of the observed changes in 35S-PGs. Changes in sulfation can be 
investigated by radiolabelling of both sulfate and sugar residues, using 35S-sulfate and 
3H-GlcN and disaccharide analyses of HS and CS. GAG-chain length could be 
investigated trough 35S-sulfate labelling of GAGs after separation from the protein 
core. GAGs could then be separated into CS and HS by CS/HS degradation, before 
separated according to size. Labelling of core proteins with for instance 35S-cys/met 
and the GAG chains with 3H-GlcN, make it possible to detect changes in GAG / core 
ratio. Also, a change in PG could be due to changes in degradation rather than 
synthesis, which also would be an interesting field of continuing research. Regarding 
quantitative analyses of individual PGs, Western blotting protocols should be 
optimized. Alternatively, ELISA assays could be used.  
Finally, the composition of the 220 kDa PG band observed on SDS-PAGE was not 
evaluated in these experiments. This band was shown to consist of HSPGs, but the 
individual PGs were not identified. The HS/CS PG syndecan-1 has been identified in 
HUVEC by in our lab only by immunoprecipitation, but we have not been able to 
reproduce these results by western blotting or ELISA assays, and further studies are 
clearly needed. Another possible candidate, however, is the HS/CS PG serglycin. 
Current experiments are performed in our lab, both Western blotting and ELISA 
assays, in order to elucidate if serglycin might be the 220 kDa PG found in HUVEC.  
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7. Conclusions 
There is need to increase our knowledge of the molecular mechanisms linking 
hyperglycemia to the pathogenesis of diabetic complications. A change in the 
endothelial expression of PGs in diabetic conditions might constitute a piece of the 
puzzle, and this was further investigated in this work.  
Perlecan was demonstrated to be a HSPG in HUVEC. Additionally, 35S-
macromolecules purified by gelfiltration, was shown to be predominately PGs, and 
this method could be used further as a descriptive tool of the de novo biosynthesis of 
PGs. 
Exposure of GlcN as an inducer of hyperglycemic effects, without affecting cell 
viability but still affecting PG expression, should be performed with GlcN 
concentrations close to 1.0 mM in HUVEC. The major findings of this study revealed 
a decreased biosynthesis and secretion of 35S-PGs and of the individual PGs perlecan 
and decorin in HUVEC exposed to 1.0 mM GlcN for 24 hours. This suggests an 
effect of glucose in hyperglycemia on the total PG expression trough the hexosamine 
pathway. The effects of exposing HUVEC to high levels of glucose were 
inconclusive. The HS/CS composition of PGs was not altered, neither with high 
glucose nor GlcN.  
Exposure of HUVEC to the proinflammatory cytokine IL-1α increased the total de 
novo synthesis of PGs, while the effects of TNF-α were more inconclusive. The 
HS/CS composition of the PGs did not seem to be altered during these conditions. 
However, only decorin was increased by cytokine stimulation, while the level of 
perlecan appeared to be unaffected. This might indicate a different effect on the 
expression of various PGs in inflammation.  
Atherosclerosis is associated with a decrease in HSPGs in endothelial cells. 
Contrastingly, an increase in PGs was seen upon IL-1α exposure. Thus, whether a 
reduction in HSPGs is linked to inflammation or not, is yet to be determined. 
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Alternatively, in addition to synthesis and degradation, other alterations of HSPGs 
could be of importance during inflammation, such as changed GAG composition, 
length or sulfation.  
Additional analyses are clearly demanded in order to make any conclusions regarding 
the causes of the observed changes in PG expression. The experiments with IL-1α 
and TNF-α must be repeated with more cell cultures, in order to verify the indicated 
trends. Additionally, the cause of the observed changes in 35S-PGs must be found, by 
investigation of core proteins and GAG composition, length and sulfation. The 
different PGs expressed by endothelial cells should also be determined in further 
detail, including studies on syndecan-1 and serglycin. 
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8. Appendix I - Materials  
8.1 Cells 
Human Umbilical Vein Endothelial Cells  
(HUVEC)  
Rikshospitalet, Norway 
8.2 Chemicals 
2-mercaptoethanol C2H6OS Sigma Aldrich, Germany 
35S-sulfate as Na2SO4 Perkin Elmer, USA 
Acetic acid /HAc, glacial (CH3COOH) Merck, Germany 
Ammonium bicarbonate (NH4HCO3) VWR, Germany 
Amplifier Amersham Biosciences, UK 
Antibodies primary:   
 decorin goat R&D systems, USA 
 perlecan rabbit Polyclonal Gift from Iozzo, R.(Department of Pathology, 
Anatomy and Cell Biology and the Kimmel Cancer 
Centre, Thomas Jefferson University, Philadelphia, 
Pennsylvania 19107, USA) 
Antibodies, secondary:  
            Anti goat HRP-linked,  R&D systems, USA 
            Anti rabbit HRP-linked Amersham, UK 
Barium nitrite (BaN2O4xH2O) Sigma Aldrich, USA 
BC Assay: Protein Quantification kit Uptima Interchim, France 
Bromophenol blue Sigma Aldrich, Norway 
BSA (Bovine Serum Albumin) Sigma Aldrich, Germany 
Charcoal, activated Merck, Germany 
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Collagenase 0.2% Sigma Aldrich, Germany 
Chondroitin ABC lyase  Sigma Aldrich, Germany 
Coomassie Blue R250  BIO-RAD, USA 
D-(+)-Glucosamine hydrochloride (GlcN 
HCl) 
Sigma Aldrich, Norway 
D-(+)-Glucose Sigma Aldrich, USA 
DEAE (diethyl aminoethyl)  Sephacel, Amersham Biosciences, Sweden 
DMSO (dimethyl sulphoxide) Sigma Aldrich, Germany 
ECL Western blotting detection reagent, 
(Advance, Plus) 
Amersham, UK 
EDTA (ethylene diamine tetraacetic acid) Merck, Germany 
EGF (Epidermal Growth Factor) R&D Systems, UK 
FCS (Foetal Calf Serum) Sigma Aldrich, Germany 
FGF (Fibroblast Growth Factor) R&D Systems, UK 
Fungisone GIBCO Invitrogen Corporation, UK 
Gentamicine  GIBCO Invitrogen Corporation, UK 
Glycerol Sigma Aldrich, Germany 
Glycine Sigma Aldrich, Germany 
Guanidine hydrochloride Fluka Bio Chemica, Germany 
Hydrocortisone Sigma Aldrich, Germany 
Hydrogen Chloride (HCl) Merck, Germany 
IL-1α (interleukin-1 α)  R&D systems, UK 
Insulin Actrapid® Pennfill® Novo Nordisk AS, Denmark 
Isopropanol Arcus, Norway 
MCDB 131 medium basis powder Sigma Aldrich, USA 
Methanol Merck, Germany 
Precision Plus protein standard, All blue BIORAD, USA 
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Precision Plus protein standard, Dual Colour BIORAD, USA 
Protease inhibitor Complete Mini EDTA-
free cocktail tablet 
Roche, Germany 
Purified MQ water (mQH2O) Elix Millipore, USA 
Rainbow 14C methylated protein molecular 
weight standard 
Amersham Biosciences, UK 
RPMI 1640 sulfate free medium GIBCO Invitrogen, Norway 
SDS (sodium dodecyl sulfate) Sigma Aldrich, Norway 
Sephadex G50-fine GE Healthcare, Sweden 
Skim Milk Powder Fluka, Switzerland 
Sodium Acetate (NaAcx3H2O)  Merck, Germany  
Sodium Carbonate (Na2CO3)  Sigma Aldrich, USA 
Sodium Chloride (NaCl) Merck, Germany 
Sodium deoxycholate  Sigma-Aldrich, USA 
Sodium Hydrogencarbonate, (NaHCO3) Kebo, Denmark 
Sodium Hydroxide (NaOH) Merck, Germany 
Sodium Pyrophosfate (Na4PO2O7) Sigma Aldrich, USA 
Sulfuric Acid (H2SO4) Merck, Germany 
TNF-α (tumour necrosis factor- α)  R&D systems, UK 
Trisma base Calbiochem, USA 
Trisma HCl Sigma Aldrich, UK 
Triton X-100 Sigma Aldrich, UK 
Trypan blue solution Sigma Aldrich, UK 
Trypsin / EDTA Sigma Aldrich, Norway 
Tween®-20 Sigma Aldrich, Germany 
Ultima Gold XR Scintillation fluid Laborel AS, Norway 
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8.3 Equipment 
96 well ELISA microplate Greiner bio-one, Germany 
Autoradiography cassette, HypercassetteTM Amersham Biosciences, UK 
Cell culture flasks (25, 75, 150 cm2) BD Labware, USA 
Cell culture plastic plates (6 and 12 wells) BD Labware, USA 
Compresses, Meosoft Tendra, Sweden 
Criterion Precast Gel, 4-20% Tris-HCl, 
12+2 & 18 wells 
BioRad, USA 
Criterion TM gel system, for SDS-PAGE and 
Western blotting 
BioRad, USA 
Eppendorf tubes (1,5 ml & 2,0 ml) Sarstedt, Germany 
Falcon pipette tubes 5, 10, 25 ml BD Labware, Germany 
Falcon tubes, 15 and 50 ml BD Labware, USA 
Filter flask (for medium), sterile TPP, Switzerland 
Finnpipette Thermo labsystems, Finland 
Glass wool Paragon, UK 
Hemacytometer, Bürker Marlenfield, Germany 
Hyperfilm ECL, Amersham GE Healthcare, UK 
Microcon Centrifugal Filter Devices Millipore corporation, USA 
pH paper Merck, Germany 
Pipetboy IBS Integra Biosciences 
Pipette tips FinnTip, Thermo Electron Corporation & 
TipOne, Starlab, GMBH, Germany 
PVDF membrane, ImmobilionTM Transfer 
Membranes 
Millipore, USA 
Scalpel, single use Paragon, UK 
Sterile needle, Sterican Braun, Germany 
Sterile surgical glows with biogel coating Regent, USA 
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Syringe filter 0.2 μm, sterile VWR 
Syringe, single use 15/50 ml, Omnifix® B.Braun, Germany 
Whatman® filter paper Schleicher & Schwell 
 
8.4 Apparature 
Centrifuge   
          Centrifuge 5417C Eppendorf 
          Centri Kubota 5930 Kubota 
          DNA speedvac, DNA 100 Savant 
          IEC Centra –M centrifuge Heigar 
          Labofuge 400 Heraeus 
Film developer AGFA Curix 60  
Freeze-dryer Hetosicc 
Gel dryer, SGD 2000 Slab Gel Dryer Thermo Savant 
Gel Imager Gel Logic Imaging system, Olympus 
Incubator, 37°C, 5% CO2  
          Mini Galaxy A E. Pedersen & Sønn laboratorieutstyr 
          Forma Scientific Incorporation 
Liquid Scintillation counter. Win spectral 
1414 
Wallac 
Magnetic stirrer, heated Heigar 
Microscope, Olympus CKX415F Olympus Corp. 
pH meter, pHM210 Radiometer Analytical 
Scale, Mettler Toledo 
Shaker  
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          Celloshaker variospeed Vialta 
          Bibby Stuart Scientific 
Titertek Multiscan PLUS, absorbance 
measurer 
Eflab 
Water bath Lauda 
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9. Appendix II - Solutions 
Cord buffer 
Components Volume Final concentration 
Streptomycin 0.5 g in 1.0 mL sterile mQ-H2O 50.0 mg/l 
1xPBS (sterile) 1000 ml  
 
1.0 L 10xPBS, pH 7.4 – stock solution 
Components Volume Final concentration 
NaH2PO4· 2H2O (Mm 120 g/mol) 8.6 g 0.072M 
KH2PO4 2.5 g 0.018M 
NaCl 85 g 1.45M 
mQ-H2O Up to 1000 ml  
pH was adjusted to 7.4 with 3M HCl or 4M NaOH. Autoclaved if needed.  
1.0 L 1xPBS, pH 7,4  
Components Volume  Final concentration 
10xPBS 100 ml 1x 
mQ-H2O 900 ml  
Autoclaved if needed 
1.0 L 0.1M Acetate buffer pH 6,5 
Components Volume Final concentration 
NaAc (NaC3H3O2·3H2O) 13.608 g 0.1M 
mQ-H2O Up to 1000 ml  
0.2M HAc was added until pH 6.5 
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1.0 L 1.0M Tris buffer, pH 8, stock solution 
Components Volume Final concentration 
Tris base C4H11NO3 121.1 g 1.0 M 
mQ-H2O 800 ml  
HCl concentrated 42 ml  
mQ-H2O  Up to 1000 ml  
pH was adjusted to 8.0 with HCl 
1.0 L 1.0M Tris buffer, pH 7.4, stock solution (for RIPA-buffer) 
Components Volume Final concentration 
Tris base C4H11NO3 121.1 g 1.0 M 
mQ-H2O 800 ml  
HCl concentrated 70 ml  
mQ-H2O  Up to 1000 ml  
pH was adjusted to 7.4 with HCl 
1.0 L 0.05M Tris buffer, pH 8.0 (for G50 Fine buffer and ion exchange buffers) 
Components Volume Final concentration 
1.0 M Tris buffer pH 7,4 50 ml 0.05 M 
mQ-H2O 950 ml  
pH was adjusted to 8.0 
1.0 M Tris buffer pH 6.8 (for sample buffer) 
Components Volume Final concentration 
Tris base C4H11NO3 121.1 g 1.0 M 
mQ-H2O 800 ml  
HCl concentrated Until pH 6.8  
mQ-H2O  Up to 1000 ml  
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0.2 M HAc/Acetic acid 
Components Volume  Final concentration 
Glacial acetic acid (17,3M) 1.0 mL 0.2M 
mQ-H2O Up to 86.5 ml  
 
100 ml 10.0 M HCl 
Components Volume Final concentration 
HCl concentrated (12,1M) 30 ml 10M 
mQ-H2O Up to 100 ml  
 
100 ml 1.0 M HCl 
Components Volume Final concentration 
10M HCl 10 ml 1.0M 
mQ-H2O Up to 100 ml  
 
10.0 M NaOH 
Components Volume Final concentration 
NaOH 40g 10M 
mQ-H2O Up to 100 ml  
 
1.0 M NaOH 
Components Volume Final concentration 
10 M NaOH 10 ml 1.0 M 
mQ-H2O Up to 100 ml  
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100 mL 4.0 M NaCl (for ion-exchange chromatography) 
Components Volume Final concentration 
NaCl 23.38 g 4.0 M 
mQ-H2O Up to 100 mL  
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